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W1LBOURN OPINION ON CAUSTIC SULPHITE CARAMEL 
EXPRESSED ON 14 DECEMBER 1990 
Note 
At its 76th plenary meeting on 13 -14 December 1990, the Scientific Committee for Food completed its 
evaluation of caustic sulphite caramel (caramel colour Π). The opinion, which has not previously 
been published, was as follows: 
"The Committee considered caustic sulphite caramel in its 14th report and again in its 
21st report. On the latter occasion, the Committee concluded that caustic sulphite 
caramel was temporarily acceptable pending provision of further information on the 
composition and homogeneity of caramels falling within this class. 
The Committee was provided with additional information indicating that the 
composition of caustic sulphite caramel is similar and intermediate to that of plain 
caramel (caramel colour I) and ammonium sulphite caramel (caramel colour IV). It was 
satisfied that the existing toxicity data on caustic sulphite caramel and ammonium 
sulphite caramel, with which it has many similarities, provide adequate documentation 
for the safety in use for both these classes of caramel. 
The Committee therefore decided to include caustic sulphite caramel within the ADI of 
200 mg/kg bw it had already established for ammonium sulphite caramel. It stressed 
that the colours should fall within the specifications established when these classes of 
caramel were previously discussed." 
References 
Reports of the Scientific Committee for Food 14th Series, EUR 8752,1983. 
Reports of the Scientific Committee for Food 21st Series, EUR 11617,1989. 
Caramel Colour II: toxicological and chemical properties. Monograph prepared by the Internationa] 
Technical Caramel Association, Washington DC, August 1990 and submitted to the European 
Commission by the European Technical Caramel Association, 3 September 1990. 
Reports of the Scientific Committee for Food (Thirty-sixth series) OPINION ON AMMONIA CARAMEL AS A FOOD COLOUR 
EXPRESSED ON 25 JUNE 1993, TEXT ADOPTED 17 JUNE 1994, REVISED 10 NOVEMBER 1994 
1. Terms of reference 
To advise on the safety in use in food of ammonia caramel (E 150c, caramel colour ΙΠ). 
2. Background 
Caramel colours have been evaluated previously by the Committee and its opinion has been 
published in its report series numbers 1, 8,14, and 21 (SCF 1974,1979,1984, and 1989). 
In its most recent previous opinion, expressed on 10 December 1987, the Committee established an ADI 
of 0-200 mg/kg bw for ammonia caramel, but made it temporary pending a review of further studies 
and especially of the attempts to reduce the content of the lymphopenic compound THI (2-acetyl-4(5)-
tetiahydroxybutylimidazole) from 25 mg of THI/kg to 10 mg of THI/kg ammonia caramel colour. 
3. Current review 
Since the last review by the SCF a considerable number of studies have been published on the colour 
itself and especially on the effect of THI on the lymphocytes and on the immune system as a whole. 
The relevant industrial organisation, the European Technical Caramel Association, has submitted a 
review of the major safety studies to date on ammonia caramel (Chappel 1992a). Furthermore, the 
journal Food and Chemical Toxicology in 1992 dedicated an issue to studies on caramel colours 
(Chappel (ed.) 1992b). 
The present review has concentrated on the most recent studies on the colour and on ΊΉΙ and has 
included two recent doctoral dissertations and a recently published study on human volunteers 
(Houben 1992, Gobin 1991, and Houben et al. 1992). A summary of the toxicological studies considered 
is given as an annex to this opinion. 
4. Discussion 
Neither the results of long-term studies in rats and mice nor the outcome of the available genotoxicity 
studies give rise to particular concern. 
The major toxicological problem associated with the intake of ammonia caramel is the adverse effect 
of THI on the lymphocytes and the immune system as a whole. So far this effect has only been 
observed in rats and mice. It is believed that the effect would also occur in man, although humans may 
be less sensitive than rats (MacKenzie et al. 1992). 
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The effects of THI depend on the level of vitamin B6 in the diet and for the estimation of a no-effect-
level or NOAEL, the interaction with vitamin B6 intake presents a difficulty. In the use of ammonia 
caramel as a food additive (with active "contaminant" THI) a safe level would be influenced by the 
level of vitamin B6 in the diet of the actual consumer, which adds to the uncertainty. 
In the most recent studies in rats on ammonia caramel and on THI the authors suggested NOAELs to be 
20 g/kg bw for ammonia caramel and to be 120 μg/kg bw of THI in female rats. In male rats the 
NOAEL for THI was somewhat higher: 380 μg/kg bw (MacKenzie et al. 1992). It should, however, be 
emphasised that in these studies the immunotoxic effects found by others and mentioned below under 
(i) were not investigated. The NOAELs in the ammonia caramel study with high ΤΉΙ content (200 
mg/kg of colour) and with THI itself might in fact have been lower if these other parameters had 
been included. 
Houben's work (1992) suggest a potential Lowest Observable Adverse Effect Level of 20 μg/kg bw of 
THI. This would give a factor of 10 between this potential LOAEL and intake of THI if the ADI were 
to be set at 200 mg/kg bw for ammonia caramel with a ΤΤΠ content of max. 10 mg/kg of colour. 
The question for the SCF was whether this could be judged satisfactory from a safety point of view. In 
reaching this judgement it should be borne in mind that: 
(i) in the recent studies in rats effects other than lymphopenia have been detected including 
changes in immune function parameters (Houben 1992 and Houben et al. 1992). The 
detectable effects were on the thymus and peripheral lymphoid tissues and effects were 
observed in mitogenic stimulation assays ex vivo. These effects were clear and 
reproducible, and they are the basis for the difference between the apparent NOAEL in 
the MacKenzie et al. studies (1992) on THI and the results reported by Houben (1992). 
(ii) in the studies in rats by MacKenzie et al. (1992) one of two samples of ammonia caramel 
used seemed to be a commercial sample with a THI content of 10 mg/kg colour. This THI 
content is exactly vhat the SCF requested in its 21st report (SCF 1989). 
(iii) on the other hand a study in human volunteers, albeit of short duration (8 days), did not 
show any adverse effect of an oral dose of 200 mg/kg b.w. of caramel III with a THI 
content of 23 and 143 mg/kg caramel (Houben et al. 1992). The elderly male volunteers in 
the study were selected to be biochemically marginally deficient in vitamin B6. The 
effects studied included, besides lymphocyte count and other haematological parameters, 
also some of the sensitive immunological parameters, which in rats were affected within 
a few days of low doses of THI (Houben 1992). 
5. Conclusion 
On the basis of the data received, the Committee decided to allocate a full ADI of 200 mg/kg bw for 
ammonia caramel with the proviso that the THI content should not exceed 10 mg/kg colour. 
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SUMMARY AND EVALUATION OF TOXICOLOGICAL STUDIES CONSIDERED 
1. Chronic toxicity and carcinogenicity 
It seems clear from the earlier evaluation of short- and long-term studies that the major adverse 
effect of ammonia caramel is the lymphopenic and immunomodulatory effects chiefly caused by ΤΉΙ, 
but dependent on the dietary intake of vitamin B6. Long-term studies in rats and mice have not 
indicated any carcinogenic potential. 
2. Genotoxicity 
Conflicting results have been published regarding genotoxic effects of ammonia caramel, which has 
been tested in various in vitro and in vivo systems covering different genetic endpoints. Negative or 
weak positive mutagenic effects in various strains of Salmonella typhimurium have been observed 
(Jensen et al. 1983, Yu et al. 1984, Aeschbacher 1986, Allen et al. 1992, Brusick et al. 1992). Conflicting 
results have been obtained with the yeast Saccharomyces cerevisiae, as ammonia caramel has been 
reported to increase the frequency of gene conversion in strain D7 up to 15 fold in non-toxic 
concentrations (Rosin et al. 1992), whereas two samples of ammonia caramel did not induce increased 
gene conversion using the yeast strain D4 (Brusick et al. 1992). Negative or weak positive clastogenic 
effects have moreover been reported in CHO cells (Allen et al. 1992, Brusick et al. 1992, and Stich et 
al. 1981) and in a test for gene mutation in L5170Y cells, both in vitro. In vivo studies were all 
negative (Brusick et al. 1992, Kawachi et al. 1980). 
In the latest investigations, where well defined commercially important caramel colours have been 
tested, consistently negative results have been obtained with the Ames test. Moreover it appeared 
that the weak positive effects found in the test with mammalian cells in vitro were found at 
relatively high doses and in the absence of exogenous mammalian metabolic enzymes. 
The overall partem of genotoxicity found with ammonia caramel gives little cause for concern with 
respect to potential genotoxic effects in humans. 
3. Short-term studies on ammonia caramel and THI in the rat 
(MacKenzie et al. 1992) 
1.13-week study on ammonia caramel 
Groups of 20 rats (7 weeks old at the start) of each sex were given 0,10,15 and 20 g low THI (10 mg/kg) 
caramel and 20 g of high THI (200 mg/kg) in the drinking water for 13 weeks. The diet contained 15 mg 
of pyridoxine/kg diet. The treated rats had soft stools, but no other treatment related clinical effects 
or deaths were noted. There was not any treatment related pathological changes in the large number 
of organs and tissues examined by gross and microscopical post mortem examination. 
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The clinical pathology tests performed were haematology, blood chemistry and urinanalysis. The 
only toxicologically significant finding was decreased white blood cell and lymphocyte counts, and 
increased neutrophil counts. This was seen at 2 weeks and at 6 weeks in animals given 20 g high ΤΉΙ 
caramel/kg bw with a return to normal values at 13 weeks. 
This finding is consistent with an ADI of 200 mg/kg bw for the low THI containing caramel (10 mg 
ΤΉΙ/kg of colour). 
2. 4-week study on THI 
Groups of 20 rats of each sex were given 0, 0.9, 7.2 mg/kg bw THI and groups of 10 rats were given 0.1, 
0.2, 0.5, 1.9 and 3.7 mg/kg bw THI in the drinking water. After 4 weeks 10 of the rats in 0, 0.9 and 7.2 
mg/kg group were given water without THI for a 2 weeks recovery phase. The mean body weight of 
all test groups were decreased during 2. and 4. weeks of the study. These changes were ascribed to 
fasting for blood sampling and urinanalysis. 
Gross and microscopical pathology of 10 animals of each group did not show treatment related effects. 
Clinical pathology tests consisted of haematology, blood chemistry and urinanalysis. Haematology 
showed treatment related lowering cf total white blood cell and lymphocyte counts and higher 
neutrophil counts. The haematological changes returned to normal by the 3rd day of the recovery 
phase and remained normal. 
The NOEL for the only important haematological effect of THI noted, the reduction in lymphocyte 
count, was 380 μg/kg bw for males and 120 μg/kg bw for female rats. However, some more sensitive 
immunotoxicological parameters studied by G. Houben (1992) were not included. 
4. Studies on lymphopenia, immunomodulation and interaction with vitamin Bg 
(a). It was found that synthetic THI rapidly produces profound lymphopenia in the rat. The 
lymphopenia was shown to result in depletion of T and B lymphocytes from peripheral blood. No 
changes in T and B cell numbers in bone narrow and spleen was found, but in the thymus THI 
administration produced a decrease in immature cells (double positive CD4+ and CBS+ cells) and an 
increase in mature cells (single positive CD4+ and CDg+ cells). The lymphopenia by THI did not seem 
to be produced by reduced production of lymphocytes as the normal proliferative activity of all 
lymphoid organs was not affected - as measured by cytofluorometric analysis of 5-bromodeoxy-2'-
uridine incorporated in vivo (Gobin 1991). 
The immune competence of rats given THI was studied by assessing induced delayed hypersensitivity, 
graft versus host and mitogen proliferation assays to test T cell function. It can be concluded that 1ΉΙ 
suppressed cell mediated immunity. THI had no direct effect when added to lymphocyte cultures from 
untreated animals. However, lymphocyte cultures prepared from THI dosed rats did not proliferate in 
vitro, suggesting that THI might act through a mediator (Gobin 1991). 
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(b). In Houben's dissertation (1992) studies were performed in Wistar rats on ammonia caramel and 
THI under the influence of dietary pyridoxine. No difference in effects of caramel or THI on the rat 
immune system were observed, which confirmed results of earlier studies that the effects of ammonia 
caramel on the immune system are caused by THL The effects were less pronounced or absent in rats fed 
a diet high in pyridoxine. THI did not induce obvious effects on vitamin B6 status. 
The effects induced by ammonia caramel and THI were reduced cell number in blood, spleen and lymph 
nodes, due to a comparable decrease in Τ and Β lymphocyte numbers. In thymus an increase was seen in 
the number of mature medullary thymocytes and a decrease in the number of ER4+ (recent thymus 
emigrants) in the spleen indicates a diminished migration of mature cells from thymus to the 
periphery. This increase in the number of mature cells was also indicated by an increase in mitogen-
induced thymidine incorporation by thymocytes from THI exposed rats. 
Further evidence for a change in the function of accessory cells was demonstrated in ex vivo studies as 
splenic cells from THI (and caramel) exposed rats did not show adequate response upon mitogenic 
stimulation. 
Similar effects of THI and ammonia caramel adininistration to those observed in rats were observed in 
mice on a basic diet with 2-3 ppm vitamin B6. 
According to the review in this report spontaneous vitamin B6 deficiency in humans is not seen 
frequently, but it may occur under certain conditions, secondary to disease or inborn errors in 
metabolism. Of more general interest is that several human populations may have an increased risk 
of marginal deficiency of vitamin Bg. Among these are chronic alcohol abusers ( NB: heavy drinkers 
of dark beer may have a high intake of ammonia caramel), females on oral contraceptives, pregnant 
women, breast-fed infants and elderly women and men. This last group was studied in a detailed study 
on human volunteers given ammonia caramel (see below). 
In the concluding part of the report the author emphasises that a consistent NOEL for ammonia 
caramel and THI has not been reported yet, mainly due to the interference of vitamin B6 in the diet. In 
addition, besides lymphopenia, other effects of these compounds have been observed on immune 
function parameters e.g. the immuno-histologically detectable effects are clear and reproducible on 
thymus and peripheral lymphoid tissues and the effects in ex vivo mitogenic stimulation assays. 
These seem only partly preventable by increasing vitamin B6 to 10-12 ppm in the diet. The author 
concludes that the Lowest-Observed-Effect-Level in the rat so far suggests a No-Effect-Level for THI 
below 20 μg/kg bw in rats fed a diet with 2-3 ppm vitamin B6. For an ammonia caramel with 25 mg of 
THI/kg this would be equivalent to an intake below 800 mg/kg bw (MacKenzie et al. 1992). 
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5. Study of ammonia caramel in human volunteers 
In a double blind intervention study by Houben et al. (1992) groups of 8 male human volunteers (above 
65 years of age) were given 0, 100 mg per kg bw (twice daily in a dessert) ammonia caramel (with 23 
mg THI/kg) and 100 mg of ammonia caramel (with 143 mg THI/kg) in a dessert for 7 days. This dose is 
equivalent to the present temporary ADI. The participants were selected to be biochemically 
marginally vitamin B6 deficient (decrease in plasma pyridoxal 5'-phosphate and increase in a-
EAST). Ammonia caramel and high vitamin B6 items were excluded from the diet 2 weeks prior to and 
during the experiment. 
Base values of haematological and clinical-chemical parameters were obtained at two weeks before, 
one week before and at the start of the study. No effect of the intake of ammonia caramel with 23 and 
143 mg of THI/kg were observed on blood lymphocyte numbers (total and within subsets) or on prolife­
rative responses to mitogenic stimulation. In addition no effect was seen on other haematological 
parameters including serum immunoglobulin levels and on immunogen production in vitro by pokeweed 
mitogen-stimulated mononuclear blood cells. The authors emphasise that all effects on haemato­
logical and immunological parameters in rats are observed within a few days (see also Houben 1992) 
and that it, therefore, was found sufficient to conduct the study in humans for a period of seven days. 
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EXPRESSED ON 16 DECEMBER 1994 
1. Terms of reference 
To advise on the safety in use of carnauba wax. 
2. Background 
Carnauba wax has previously been evaluated by the Committee and on 19 October 1990 the substance 
was found temporarily acceptable as a glazing agent (SCF 26th Series Report, 1992). The acceptance 
was made temporary pending supplementary toxicological data and technical data on use. 
3. Current review 
Since then the WHO Joint Expert Committee on Food Additives (JECFA) has evaluated the same 
data as those evaluated by the SCF, that is, a 90-day rat study, a 28-week dog study, a combined 
reproduction and subchronic rat study, a rat teratogenicity study and in vitro mutagenicity studies in 
bacteria and yeast (WHO, 1993; Parent et al, 1983a, b; Rowland et al, 1982). The JECFA ADI of 7 
mg/kg bw was based on the no-effect level from the combined reproduction and subchronic study, in 
which no adverse effects were observed up to the highest dose level tested of 1% in the diet 
(equivalent to 700 mg/kg bw). 
No further toxicological data have been submitted to the SCF since its 26th Report, but the 
Committee has been informed that use of carnauba wax on confectionery is unlikely to exceed 200 
mg/kg. Even with high intake of treated foods it would therefore be unlikely that intake would 
exceed 1-2 mg/kg bw/day. 
4. Discussion 
The Committee noted that the structure of the main components of carnauba wax (long-chain 
aliphatic esters) raises the possibility that this wax might behave like some mineral hydrocarbons. 
The key study (Parent et al, 1983b), in which full histopathological examinations were carried out on 
the control and high-dose groups of F^ rats used for the 13 week subchronic part of the study, did 
include those organs where accumulation and toxic effects have been observed after ingestion of 
certain mineral hydrocarbons, without any effects being reported. The Committee noted, however, 
that these studies were completed before the effects of mineral hydrocarbons became known and that 
there were no absorption or metabolism data for carnauba wax. The Committee therefore requires 
information on the readiness of carnauba wax components to hydrolyse. If this cannot be shown then 
the Committee may require evidence of lack of accumulation in tissues. 
Reports of the Scientific Committee for Food (Thirty-sixth series) 11 16 DECEMBER 1994 CARNAUBA WAX 
Whilst the Committee has not received the toxicological data requested earlier, the information on 
use gives assurance that potential intake of carnauba wax will be well below the ADI allocated by 
JECFA and thus leaves a comfortable safety margin between intakes and the observed no-effect level 
in the combined reproduction and subchronic rat study. However, where there are no carcinogenicity 
studies, then the mutagenicity data should be adequate. There are studies on S. typhimurium TA 1535, 
1537, 1538 and 98 which covers base-pair and frame-shift point mutation endpoints (although they 
did not use the TA 100 strain). But the Committee has not been made aware of any study covering the 
endpoint of chromosome aberrations. 
5. Conclusion 
It is recommended that subject to compliance with an acceptable specification the temporary 
acceptance of carnauba wax used as a glazing agent be extended pending submission of a mutagenicity 
test covering the endpoint of chromosome aberrations in mammalian cells in vitro and information on 
the readiness of carnauba wax ester components to hydrolyse. These studies should be carried out on 
material conforming to an appropriate and acceptable specification. This information should be 
submitted within one year. 
References 
Parent RA, Cox GE, Babish JG, Gallo MA, Hess FG and Becci PJ (1983a). Subchronic feeding study of 
carnauba wax in beagle dogs. Food Chemical Toxicology, vol 21, 85-87. 
Parent RA, Re TA, Babish JG, Cox GE, Voss KA and Becci PJ (1983b). Reproduction and subchronic 
feeding study of carnauba wax in rats. Food Chemical Toxicology, vol 21, 89-93. 
Rowland IR, Butterworth KR, Gaunt LF, Grasso Ρ and Gangolli SD (1982). Short-term toxicity study of 
carnauba wax in rats. Food Chemical Toxicology, vol 20, 467-471. 
SCF (1992), Scientific Committee for Food 26th Series Report. European Commission, Luxembourg. 
WHO (1993), Toxicological evaluation of certain food additives and naturally occurring toxicants: 
Carnauba wax. WHO Food Additive Series: 30. World Health Organisation, Geneva. 
12 Reports of the Scientific Committee for Food (Thirty-sixth series) OPINION ON COUMARIN 
(A CONSTITUENT OF NATURAL FLAVOURING SOURCE MATERIALS 
LIMITED BY ANNEX Π OF FLAVOURINGS DIRECTIVE 88/388/EEC) 
EXPRESSED ON 16 DECEMBER 1994 
1. Terms of reference 
To review the toxicity of coumarin in the light of recently completed studies and to consider whether 
the limits for coumarin in food set out in Annex II of the flavourings Directive 88/388/EEC (EEC, 1988) 
need to be amended. 
2. Background 
Coumarin is a naturally occurring benzopyrone. It occurs in various plants including tonka beans and 
sweet clover and in several natural flavouring source materials. Coumarin itself was originally used 
as a flavouring substance until the direct use of coumarin in food was prohibited in the USA in 1954 
following reports of hepatotoxic effects in rats and dogs. It is still used in fragrances and tobacco. More 
recently, it has been used in the medical treatment of high protein lymphoedema and chronic 
infections such as brucellosis and tuberculosis. Coumarin has also been investigated in the treatment of 
renal cell carcinoma, malignant melanoma and prostate cancer. 
Coumarin is listed in the 3rd Edition of the Council of Europe 'Blue Book' (Council of Europe, 1981) as 
an 'active principle'. The Council of Europe defines an active principle as a constituent of a natural 
flavouring source material for which, due to existing toxicological data, it appears necessary to set a 
maximum concentration limit in foodstuffs as consumed. No substance included in the list of active 
principles is approved by the Council of Europe for use as a chemically-defined flavouring substance 
in its own right. For coumarin, the general limits are < 2 mg/kg in food and beverages with specific 
exceptions of 10 mg/kg in "special" caramels and 10 mg/kg in alcoholic beverages. It should be noted 
that the Council of Europe considered that the general limit in food and beverages should be less than 
2 mg/kg, but that methods of analysis generally available at the time did not permit a lower level of 
detection. 
The SCF examined the Council of Europe list of active principles in 1979 and considered that allowing 
the continued use of natural flavouring source materials with limitation of the active principles 
represented a practical approach (CEC, 1979). The Council of Europe limits were endorsed with the 
addition of another exception of 50 mg/kg in chewing gum. The SCF limits for coumarin are included in 
Annex II of the EC Flavourings Framework Directive 88/388/EEC. That annex sets 'maximum limits 
for certain substances obtained from flavourings and other food ingredients with flavouring properties 
present in foodstuffs as consumed in which flavourings have been used'. In other words, the limit only 
applies if flavourings have been added to a foodstuff but refers to the total amount of coumarin 
present in that foodstuff from either food ingredients or the flavouring. Annex II of the directive also 
contains a footnote indicating that the substances listed may not be added as such to foodstuffs or to 
flavourings. 
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Recently, a draft report of a US National Toxicology Program carcinogenesis bioassay on coumarin has 
been published (NTP, 1992a) and so the SCF has been asked to review coumarin. In the current review, 
the Committee has looked again at the earlier published toxicological studies on coumarin, as well as 
taking account of the recent NTP work and other studies published since our last review. The 
Committee was asked to consider whether the limits for coumarin in food, which apply when natural 
flavouring source materials are added to food, as set out in Annex Π of the flavourings Directive, need 
to be amended. The SCF was not asked to consider coumarin as a chemically defined flavouring 
substance since it is currently prohibited for that purpose, nor was it asked to consider the context of its 
occurrence solely as a natural toxicant in foodstuffs. 
3. Discussion 
Coumarin is hepatotoxic to rats and dogs, causing liver enlargement, focal necrosis, fibrosis and bile 
duct proliferation. Other species however appear to be more resistant to the hepatotoxic effects of 
coumarin. 
In rats, clear evidence of hepatotoxicity has been seen after dietary administration of doses in the 
range 87-125 mg/kg bw/day and above (HRC, 1984; Brune, 1984; Cohen, 1979) and after oral gavage 
doses of 25 mg/kg bw/day and above (NTP, 1992a). In addition to hepatotoxicity, studies have also 
shown coumarin caused cholangiocarcinomas and hepatocellular carcinomas. These were seen in both 
sexes at dietary doses of 230-340 mg/kg bw/day in two chronic studies on Sprague-Dawley rats in 
which doses ranging from 13-283 mg/kg bw/day (HRC, 1984) or 10-340 mg/kg bw/day (Brune, 1984) 
were given. Cholangiocarcinomas were not observed at doses of 87-110 mg/kg bw/day and below in 
these two studies. No cholangiocarcinomas or hepatocellular carcinomas were seen in the one chronic 
study in F344 rats in which coumarin was given by gavage at doses of 25, 50 or 100 mg/kg bw/day 
(NTP, 1992a). Several of the earlier 90 day and 2 year rat dietary studies have shown 1000 ppm 
(approximately 50 mg/kg bw/day) to be a no effect level for histological liver damage (Cohen, 1979). 
Changes in liver weight and serum liver enzyme levels however are seen from lower doses of 10-25 
mg/kg bw/day when given Dy gavage (NTP, 1992a; Cohen, 1979). One of the more recent 2-year 
dietary studies has shown minor, atypical changes in the bile ducts of Sprague-Dawley rats at doses 
down to 10 mg/kg bw/day, the lowest dose tested (Brune, 1984). 
In the dog oral doses of 25 mg/kg bw/day for over 100 days caused histological liver damage, 10 mg/kg 
bw/day being a no effect level (Hagan et al, 1967). Studies in limited numbers of baboons have found 
no evidence of histological liver damage and only slight evidence of reversible biochemical, 
histochemical or ultrastructural changes after oral dosing at 50 and 100 mg/kg bw/day for 3 weeks or 
dietary administration of doses up to 67.5 mg/kg bw/day for 2 years (Cohen, 1979). It is not known 
whether doses higher than these would produce histopathological changes in the baboon. 
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Only slight liver enlargement and no hepatotoxicity was found in CD1 mice given up to 280 mg/kg 
bw/day via the diet for 2 years (HRC, 1983). In a 2-year gavage study in B6C3F1 mice given 50,100 or 
200 mg/kg bw/day, syncytial alteration and centrilobular hypertrophy were seen in the liver at 200 
mg/kg bw/day in females and in males at 100 mg/kg bw/day and above; syncytial alteration alone 
was seen at 50 mg/kg bw/day in male mice (NTP, 1992a). Significant increases in eosinophilic foci and 
hepatocellular adenomas were seen at 50 and 100 mg/kg bw/day but not at 200 mg/kg bw/day in 
female mice. In males, eosinophilic foci were increased at all doses but no hepatocellular adenomas 
were observed. In contrast to rats, no centrilobular necrosis was seen in mice of either sex. Similar 
increases in hepatocellular adenomas were seen in females in a 2-year gavage study in B6C3F1 mice 
using 3,4-dihydrocoumarin (which does not form an epoxide and causes no histopathological changes 
in rat liver) (NTP, 1992b). Also in contrast to the rat, coumarin did not cause liver necrosis in gerbils 
given a single i.p. dose of 125 mg/kg bw (Fentem et al, 1992), nor was it found to be hepatotoxic or 
hepatocarcinogenic in hamsters given up to 0.5% in the diet (approximately 600 mg/kg bw) for 2 years 
(Ueno and Hirono, 1981). 
There are major interspecies differences in coumarin metabolism and these have been intensively 
studied to see if they might provide the explanation for the observed species differences in coumarin 
hepatotoxicity. In the rat, the major urinary metabolite is o-hydroxyphenylacetic acid from 3-
hydroxycoumarin, whereas in baboons and man the major urinary metabolite is 7-hydroxycoumarin 
(Cohen, 1979). As in the rat, urinary excretion of 7-hydroxycoumarin is low in dogs, hamsters and some 
strains of mice (Cohen, 1979). One early theory of the mechanism of coumarin toxicity was that it 
would occur in species which did not form 7-hydroxycoumarin. However, the lack of hepatic effects in 
the hamster (Ueno and Hirono, 1981) suggests this is not the key difference. In the rat, recent studies 
indicate the involvement of a cytochrome-P450 generated metabolite in the hepatotoxicity of 
coumarin, possibly the formation of a hypothetical 3,4-epoxide intermediate in the oxidation of 
coumarin to 3-hydroxycoumarin (Lake et al, 1989; Fentem et al, 1992a). Other recent evidence has 
suggested that the conjugation of a coumarin metabolite with glutathione provides a detoxification 
pathway in the rat (Huwer et al, 1991). Whilst the epoxide hypothesis is plausible and there are 
several strands of evidence to support it, once again the lack of hepatotoxicity in the hamster is 
puzzling since, like the rat, hamster microsomes produce o-hydroxyphenyl-acetaldehyde and 3-
hydroxycoumarin, both of which can be derived from the 3,4-epoxide (Lake et al, 1992a). o-
Hydroxyphenyl-acetaldehyde is the major microsomal metabolite at high coumarin concentrations in 
many species including man (Lake et al, 1992a; Fentem et al, 1992b). 7-Hydroxycoumarin excretion in 
man is variable and can be as low as 10% (Cholerton et al, 1992). Alternative metabolic pathways 
used when 7-hydroxylation is low are unknown, but in vitro studies on human liver microsomes suggest 
that at high coumarin levels, when the 7-hydroxylation pathway is saturated then the o-
hydroxyphenyl-acetaldehyde pathway may be favoured (Lake et al, 1992a; Fentem et al, 1992b). 
Clinical trials in man suggest that hepatotoxicity from coumarin is rare (Cox et al, 1989; Marshall, 
1992), but it does occur. Thus the possibility that man may be susceptible to coumarin cannot be ruled 
out. 
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Tumours have been observed at sites other than the liver. In a 2-year oral gavage study on F344 rats 
given 25, 50 or 100 mg/kg bw/day (NTP, 1992a), coumarin caused a dose-related increase in chronic 
nephropathy and a low incidence of renal adenomas (but not carcinomas) at 25 mg/kg bw/day (males) 
and 50 mg/kg bw/day (females). There was no clear dose response although, in males, this could have 
been due to the poor survival because of the nephropathy at the top two doses. Similar minor effects 
on the kidney were seen in a 2-year gavage study with 3,4-dihydrocoumarin in F344 rats (NTP, 1992b). 
No such effects were seen in the rat studies in which coumarin was given in the diet (HRC, 1984). In 
B6C3F1 mice given 50, 100 or 200 mg/kg bw/day coumarin by gavage for 2 years (NTP, 1992a), lung 
adenomas in both sexes and carcinomas in females were increased at the top dose. No such effects were 
seen in 2 year dietary studies in CD-I mice given up to 280 mg/kg bw/day (HRC, 1983). 
In mutagenicity studies in vitro, coumarin has tested negative in three Ames studies (Cohen, 1979), but 
positive or weakly positive in three others in one strain of Salmonella typhimurium, TA100, in the 
presence of metabolic activation (NTP, 1992a; Norman and Wood, 1981; Stoltz et al, 1982). A further 
study using the Ames spot test was inadequate for evaluation (Florin et al, 1980). Coumarin 
selectively inhibited excision repair in E.coli WP2 cells (Grigg, 1972). It increased the frequency of 
sister chromatid exchanges in Chinese hamster ovary (CHO) cells in the absence but not in the 
presence of metabolic activation and increased chromosome aberrations in CHO cells in the presence 
but not in the absence of metabolic activation (NTP, 1992a). Mutagenicity studies in vivo, comprising a 
sex linked recessive lethal assay in Drosophila (NTP, 1992a) and micronucleus tests in blood (NTP, 
1992a) and bone marrow (Morris and Ward, 1992; Sterner and Korn, 1981) in mice, while negative, are 
of poor quality. 
4. Conclusions 
It may be concluded that coumarin is a carcinogen in rats via the oral route and possibly in mice. In 
rats, adenomas and carcinomas of the liver and bile duct and adenomas of the kidney have been 
observed. In mice, adenomas and carcinomas of the lung and liver adenomas have been observed. In 
reaching our recommendations (see below) the Committee gave particular weight to the occurrence of 
liver toxicity, including cholangiocarcinomas and hepatocellular carcinomas, confirmed in two 
chronic rat studies in which coumarin was administered by the dietary route. The results of the NTP 
gavage studies are more difficult to interpret: in rats only general liver toxicity, not tumours were 
seen, together with kidney adenomas, as well as nephropathy which is common in ageing rats; in the 
mouse significant dose-related increases were seen in lung tumours in both sexes, but significant 
increases in liver tumours were only seen in the low and mid-dose females. Both liver and lung tumours 
are common spontaneous occurrences in the strain of mouse used. Whilst not consistent with the dietary 
studies, the results from the gavage studies did not lessen our concern about the toxicity of coumarin. 
A key issue in assessing the risk of coumarin to man is deciding whether or not coumarin is genotoxic. 
Particularly strong reassurance is needed that coumarin is not genotoxic in vivo when, in addition to 
positive in vitro studies, an epoxide has been postulated as a metabolic intermediate. The 
requirement for metabolic activation for a positive response in Salmonella typhimurium TA100 and in 
a study of chromosomal aberrations in CHO cells is consistent with the idea that activation to an 
epoxide may be required. However, metabolic activation did not appear to be required for the 
induction of SCEs in CHO cells in vitro (NTP, 1992a) but the positive response without S9 was weak 
and was not dose-related. The available in vivo mutagenicity studies, while negative, are not of a 
high enough standard to provide sufficient reassurance that coumarin is not active in vivo. 
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A further key consideration is whether the carcinogenicity seen in rats and mice, if due to an epoxide, 
is relevant to man. The Committee concluded that the epoxide route cannot be ruled out in man and 
need only be a minor pathway for genotoxic/carcinogenic effects to be of concern. 
5. Recommendations 
Taking into account the natural occurrence of coumarin in natural flavouring source materials, the 
carcinogenic activity of coumarin and the fact that a genotoxic mechanism cannot be excluded at this 
point in time, the Committee recommends that: 
(i) the general limit in food and beverages for coumarin, which applies when it is present 
because natural flavouring source materials containing coumarin have been added, should 
be reduced to the currently achievable limit of detection for coumarin of 0.5 mg/kg; 
(ii) action should be taken to reduce the higher levels which are currently permitted in certain 
traditional products. 
6. Further research 
The Committee considered that further research on coumarin would be desirable, particularly if any 
proposals to raise the general limit from that now recommended (the lowest achievable limit of 
detection) were to be considered. In this regard, further mutagenicity information could be 
particularly helpful. The Committee understands that new in vitro mutagenicity studies have been 
carried out recently, under the auspices of the Research Institute for Fragrance Materials, USA, on 7-
hydroxycoumarin and ortho-hydroxyphenylacetic acid, which are the major metabolites in man and 
rat respectively. Final reports on these studies are pending. The Committee wishes to see these 
reports, but it should be stressed that these studies are on the end-stage metabolites only and thus 
they do not address the concern about the possible formation of an active epoxide intermediate. To 
address this concern, in the first instance, an in vivo bone marrow micronucleus test in mice and an in 
vivo liver UDS study in rats would be helpful. 
Further research to address the more difficult issues could also be helpful but the Committee 
recognises that the resolution of these questions is less certain and could involve extensive work. These 
issues include whether the 3,4-epoxide is indeed responsible for the toxicity of coumarin, the extent to 
which it is produced in other species including man, whether a good animal model for man can be 
found from the metabolic viewpoint, what proportion of the human population has low 7-
hydroxylase activity and how coumarin is metabolised in these people. 
Finally, no clear assessment of the likely risk to man will be possible without quantitative 
information on the levels of coumarin in various natural flavouring source materials and foodstuffs to 
allow at least a rough estimate of coumarin intake in man. 
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EXPRESSED ON 16 DECEMBER 1994 
1. Terms of reference 
To evaluate the hazards to human health arising from the migration into food of di-2-
ethylhexylphthalate (DEHP) present in certain plastic materials and articles intended to come into 
contact with foodstuffs. 
2. Background 
This substance was first evaluated by the Committee (6th Report, 1978) as part of the review of the 
positive list of substances to be authorised in the manufacture of regenerated cellulose films intended 
to come into contact with foodstuffs. This evaluation was reviewed again by the Committee (14th 
Report, 1982) in the light of a considerable number of further studies and of the entire proceedings of 
the United States' National Toxicology Program (NTP) Conference on phthalates held in June 1981 
(1). The Committee's conclusion at that time stated that DEHP had produced benign and malignant 
tumours of the liver in the mouse and the rat at the high doses used in the NCI/NTP studies. 
Although the in vitro mutagenicity tests gave conflicting results, the dominant lethal study (i.p.), an 
in vivo assay, indicated a possible genotoxic, though not dose-dependent, effect. High oral doses in 
mice had also produced embryotoxic and teratogenic effects. 
In view of these findings including the studies on mechanism and covalent binding for DEHP, the 
Committee excluded DEHP from the previously established group TDI for phthalates. 
3. Review of additional data 
A large number of additional investigations have now been provided for the Committee. They confirm 
that DEHP is hydrolysed to its monoester and 2-ethylhexanol predominantly in the intestinal tract 
and is subsequently partially absorbed. A considerable species difference exists in the degree of 
intestinal absorption. Further biotransformation occurs mainly in the liver showing again 
considerable species differences. In general, rodent species oxidise DEHP further than primates. Most 
species except the rat excrete the metabolites as glucuronides in the urine. The bulk of the compound is 
excreted in the urine and faeces within 24 hours, no tissue accumulation being observed (2,3). 
The acute toxicity of DEHP is low, major target organs being the liver and the testes (4). The most 
striking change is peroxisomal proliferation in the liver, the occurrence of which again shows marked 
species differences. For example, it is found in the liver of rats but not of guinea pigs or marmosets and 
not in vitro in human hepatocytes, suggesting that non-human primates and humans are less sensitive 
than rodents to chemical peroxisome proliferators (5,6). 
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Several oral studies in rats point to 50 mg/kg b.w., being the dose level at which liver weight 
increases and peroxisomal proliferations are induced. This is evidenced by ultramicroscopic changes in 
the liver and changes in the peroxisome-associated enzyme activities. Short term oral studies, 
including also dose levels below 50 mg/kg b.w. show inconsistent results. One 2-week study (7) by 
gavage in rats finds no increased liver weights or changes in hepatic palmitoyl CoA oxidation 
(PCoA), carnitine acetyltransferase or carnitine palmitoyltransferase activities at 25 mg/kg b.w.. 
Furthermore, no hepatic peroxisomal proliferation can be detected histochemically. However, 100 
mg/kg b.w., the next dose level, affects biochemical indicators of peroxisomal proliferation. 
A 7-day feeding study (8) reports a decrease in serum triglycerides at about 2.5 mg/kg b.w., an increase 
in carnitine palmitoyltransferase at about 5 mg/kg b.w. and an increased PCoA as well as increased 
carnitine acetyltransferase and carnitine palmitoyltransferase activities without any effect on liver 
weight at about 25 mg/kg b.w.. Ultramicroscopic hepatic changes are seen at about 250 mg/kg b.w.. 
Ultramicroscopic hepatic changes are seen at about 250 mg/kg b.w., the highest level tested. Because 
of lack of food consumption and age data of the rats, the dose levels were calculated from the dietary 
levels by using a factor of 20 instead of the usual 10 for short-term studies in young rats. 
The NOEL in a 3-week feeding study (9) in F344 rats, dosed with 0,12, 109, 643, 1197 or 1892 mg/kg 
b.w. as calculated from the food intake, is reported as 12 mg/kg b.w. based on peroxisomal 
biochemical and ultramicroscopic parameters. Another 28-day feeding study (10) in F344 rats, dosed 
with 0, 24, 52, 115, 559, 1093 or 2496 mg/kg b.w., shows 52 mg/kg b.w. as NOEL for the induction of 
PCoA. However, the absolute liver weight is increased significantly at 52 mg/kg b.w. and higher and 
the relative liver weights are increased significantly at all dose levels in a dose-related manner. 
Histopathology of the liver shows a dose-related increase in hepatocyte basophilia at 52 mg/kg b.w. 
and higher doses. 
A recent feeding study (11) in male Wistar rats used 0, 5,18, 50,180 or 500 mg/kg b.w. for either 2 or 4 
weeks. The NOEL for induction of peroxisome associated enzymes lauric acid hydrolase and enoyl 
coenzyme-Α hydratase is 5 mg/kg b.w.. Lightmicroscopic and electronmicroscopic morphometric 
analyses also show 5 mg/kg b.w. to be a NOEL. The NOEL for PCoA is 18 mg/kg b.w.. 
A 2-year feeding study (12) in rats with dose levels of 10, 100 and 1000 mg/kg b.w. shows slight 
increases at 10 mg/kg b.w. in the activities of CN-insensitive palmitoyl dehydrogenase in liver 
homogenates and in mitochondrial carnitine acetyltransferase. These changes become more 
pronounced at higher dose levels. 
DEHP has no genotoxic potential. In vitro tests for gene mutations in bacterial, eukaryotic and 
mammalian cell systems, with or without S9, are negative. Similarly, in vitro tests for chromosomal 
aberrations and sister-chromatid exchanges in mammalian cells and in vivo studies for chromosomal 
aberrations in somatic and germ cells are negative. There is no evidence for covalent binding to DNA, 
for induction of single-strand breaks in DNA or for unscheduled DNA synthesis (13). 
In long term studies, DEHP increased the incidence of hepatocellular adenomas and carcinomas in 
both mice and rats when given at high levels in the diet. The increases were dose-related at doses of 
3000 and 6000 mg/kg of diet in mice and 6000 and 12000 mg/kg of diet in rats. The lowest doses are 
equivalent to intakes of 300-430 mg/kg b.w. (4). 
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4. Proposed mechanism of action 
The ability of some compounds, including DEHP, to induce hepatocellular carcinomas in rodents has 
been linked to their ability for inducing peroxisomal activity in the liver. Peroxisomal proliferation 
is in fact an early event during treatment with these compounds and appears to be the most sensitive 
change occurring in the liver at low doses. A causal association between peroxisomal proliferation and 
hepatic tumour development has been suggested (5,14). However, the underlying mechanism of 
carcinogenicity by peroxisomal proliferation is not known and may be complex. Suggestions include: 
- oxidative stress and the induction of indirect DNA damage 
- promotion of spontaneous preneoplastic lesions 
- sustained growth stimulation. 
All these mechanisms are considered to have a threshold. They are not mutually exclusive but could 
have an additive or synergistic effect (15). 
Peroxisomal proliferation is associated in the peroxisomes with increased ß-oxidation of fatty acids 
and similar compounds. This results in an increased production of hydrogen peroxide and/or other 
active oxygen species. The excess oxygen "leaks" from the peroxisomes and causes oxidative damage to 
other intracellular components. This may also lead to direct damage to the genetic material in the 
cell nucleus and subsequent neoplastic transformation. Alternatively, cumulative oxidative damage to 
intracellular membranes can lead to cell death and increased cell turnover, thus increasing the 
probability of spontaneous tumour formation (17). 
Others claim that cell proliferation is unlikely to play a primary role in the hepatocarcinogenicity 
of peroxisome proliferators because a) the maximum proliferative response is very transient and b) 
chronic administration results in no or only a slight increase in replicative DNA synthesis. 
Furthermore, mitogen-induced liver cell hyperplasia is less predisposed to become carcinogenic and 
several potent mitogens without a peroxisomal proliferative effect are not carcinogenic (16). 
DEHP has adverse effects on reproduction. It causes foetotoxic and/or teratogenic effects in rodents. 
The NOEL for these effects in female mice, the most sensitive species, is 35 mg/kg b.w.. The NOEL for 
reproductive parameters in male and female mice is 15 mg/kg b.w (18,19). 
5. Conclusion 
The overall NOEL for DEHP in the rat, based on the peroxisomal effects in the liver as measured by 
biochemical parameters and morphometric analysis in this sensitive species in the most recent study 
(11), appears to be 5 mg/kg b.w.. An earlier study (8) points to 2.5 mg/kg b.w. as NOEL for hepatic 
peroxisomal effects. However, this study shows some deficiencies. 
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Bearing in mind the lack of genotoxicity in numerous assays using several mutagenic endpoints, the 
large margin between the doses of DEHP necessary to induce hepatic tumours (300-430 mg/kg b.w.) and 
those inducing hepatic peroxisomal activity, as well as the evidence for a threshold for increased 
hepatic peroxisomal activity enables the Committee to conclude that the very small intakes of DEHP 
from its uses in food packaging would not pose any carcinogenic hazard for man. Although the 
Committee acknowledges that some other studies might support a higher NOEL, it was unable to 
ignore the fact that lower doses still induced noticeable biochemical and electronmicroscopic changes 
and that some of these studies used different strains of rats. 
The Committee also considered the suggestion that a safety factor of less than 100 might be applied in 
establishing a TDI for DEHP because of apparent differences in sensitivity with regard to 
peroxisomal enzyme induction and metabolism between subhuman primates, man and the laboratory 
rodents. It was not convinced, however, that the evidence was sufficiently weighty to accept this 
suggestion. 
The Committee therefore retained as a matter of prudence a safety factor of 100 in establishing a TDI 
of 0.05 mg/kg b.w. for DEHP based on the NOEL for peroxisomal proliferation. 
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Reports of the Scientific Committee for Food (Thirty-sixth series) OPINION ON DI-2-ETHYLHEXYLADIPATE 
EXPRESSED ON 16 DECEMBER 1994 
1. Terms of reference 
To evaluate the hazards to human health arising from the migration into food of di-2-
ethylhexyladipate (DEHA) present in certain plastic materials and articles intended to come into 
contact with foodstuffs. 
2. Background 
This substance was evaluated by the Committee (6th Report, 1978) as part of the review of the 
positive List of substances to be authorised in the manufacture of regenerated cellulose films intended 
to come into contact with foodstuffs. This evaluation was reviewed again by the Committee (14th 
Report, 1982) in the light of a considerable number of further studies and of the entire proceedings of 
the United States' National Toxicological Program (NTP) Conference on phthalates held in June 1981 
(1). The Committee's conclusions at that time stated that the evidence regarding carcinogenicity was 
inconclusive because only in the mouse was there evidence of liver tumour induction. The only 
available mutagenicity test indicated mutagenic potential. Teratogenic and embryotoxic effects were 
only seen at high dose levels. 
In view of these findings, including studies on mechanism and covalent binding to DNA for DEHA, the 
Committee excluded DEHA from the ADI previously established for three adipates. 
3. Review of additional data 
A number of additional investigations have now been provided for the Committee. They confirm that 
DEHA is rapidly absorbed by animal species, metabolised and excreted in the urine and to a lesser 
extent in the faeces and expired air within 48 hours. Absorption is incomplete after high doses. No 
tissue accumulation is observed. Rapid hydrolysis to the monoester and 2-ethyl-hexanol (EH) as well 
as of the monoester to adipic acid and EH occurs predominantly in the intestinal tract. EH is largely 
oxidised in the liver by ω-, ω-l- and ß-oxidation to a series of metabolites. There are species 
differences in the biotransformation of DEHA. Rodents excrete largely ethylhexanoic, 5-hydroxy-2-
ethylhexanoic and ethylhexanedioic acid, while monkeys excrete predominantly mono-2-
ethylhexanoic adipate and EH as the glucuronides (2). 
DEHA has a low acute toxicity and causes little or no skin and eye irritation. 
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The liver is the major target organ in short-term studies in mice and rats, increased liver weight being 
observed at doses of 600 mg/kg b.w. and higher. In 2-3 week feeding studies in rats, using dose level: 
from 500-2000 mg/kg b.w., a hypolipidaemic effect is noted, indicated by the inhibition of cholesterol 
synthesis and an altered phospholipid synthesis. This effect is associated with hepatic peroxisome 
proliferation as observed electron-microscopically, increased activities of peroxisome-associated 
enzymes and an increased production of peroxisome proliferation-associated 80000 D polypeptide 
(PPA-80) (3). 
The NOEL for the induction of peroxisomal proliferation in 3-4 week feeding studies in F344 rats is 
around 100 mg/kg b.w. based on the activities of hepatic peroxisomal-associated enzymes and 
ultramicroscopic changes. A further 30-day feeding study in male F344 rats shows a NOEL of 250 
mg/kg b.w., based on ultramicroscopic changes and increased levels of peroxisome proliferation-
associated 80000 D polypeptide. If PCoA oxidation is considered, then 250 mg/kg b.w. cause a three-
fold rise in activity. A recent feeding study in male Wistar rats used 0, 20, 60, 200, 600 or 2000 mg/kg 
b.w. for two weeks. The NOEL for induction of peroxisomal associated enzymes was 200 mg/kg b.w. 
(14). Peroxisomal effects of DEHA are, however, moderate compared to those of DEHP. EH is 
considered to be the proximate peroxisomal proliferator. There is also a marked species difference for 
peroxisomal effects. In vitro studies with hepatocytes of rats, guinea pigs and marmosets show only in 
rat hepatocytes a clear effect (4,5). Non-human primates and humans appear to be less sensitive than 
rodents to chemically induced peroxisome proliferation (6,7). 
Although a dominant lethal assay (i.p.) in mice has been reported as showing a positive, dose-
dependent effect (8), further assays in a range of systems are negative. Thus, in vitro bacterial assays 
with and without S9, in vitro mouse lymphocyte test for DNA damage with and without S9, an in 
vivo mouse micronucleus test and a sex-linked recessive lethal test in Drosophila show no genotoxic 
activity of DEHA. A covalent DNA-binding study in mouse liver and a cell transformation test in 
BALB/3T3 mouse cells are equally negative (3). 
The previously assessed long-term studies in mice and rats, using dose levels of 1715 and 3570 mg/kg 
b.w. in mice and 600 and 1250 mg/kg b.w. in rats, showed only in mice a significantly increased 
incidence of Liver tumours. A possible explanation might be the lower dose levels used in rats (9). 
DEHA caused reduced fertility in a reproduction study in male mice at a high i.p. dose of 9220 mg/kg 
b.w. however, no testicular lesions have been reported in two 3-week feeding studies in rats and in 13-
week and 2-year feeding studies in mice and rats (3). No effects on fertility of male and female rats 
are reported in a 1-generation reproduction study using dose levels up to 720 mg/kg b.w. although at 
that dose foetotoxic effects and, in parental animals, decreased growth and increased liver weights 
are noticeable (12). DEHA has no teratogenic effects in rats at dose levels up to 720 mg/kg b.w. but 
maternal effects are present. Foetotoxic effects appear at 110 mg/kg b.w. thus establishing as NOEL 
30 mg/kg b.w (13). 
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4. Proposed mechanism of action 
The ability of some compounds, including DEHA, to induce hepatocellular carcinomas in rodents has 
been linked to their ability for inducing peroxisomal activity in the liver. Peroxisomal proliferation 
is in fact an early event during treatment with these compounds and appears to be the most sensitive 
change occurring in the liver at low doses. A causal association between peroxisomal proliferation and 
hepatic tumour development has been suggested (6,10). However, the underlying mechanism of 
carcinogenicity by peroxisomal proliferation is not known and may be complex. Suggestions include: 
- oxidative stress and the induction of indirect DNA changes 
- promotion of spontaneous preneoplastic lesions 
- sustained growth stimulation. 
All these mechanisms are considered to have a threshold. They are not mutually exclusive but could 
have an additive or synergistic effect (11). 
Peroxisomal proliferation is associated in the peroxisomes with increased ß-oxidation of fatty acids 
and similar compounds. This results in an increased production of hydrogen peroxide and/or other 
active oxygen species. The excess oxygen "leaks" from the peroxisomes and causes oxidative damage to 
other intracellular components. This may also lead to direct damage to the genetic material in the 
cell nucleus and subsequent neoplastic transformation. Alternatively, cumulative oxidative damage to 
intracellular membranes can lead to cell death and increased cell turnover, thus increasing the 
probability of spontaneous tumour formation (16). 
Others claim that cell proliferation is unlikely to play a primary role in the hepatocarcinogenicity 
of peroxisome proliferators because a) the maximum proliferative response is very transient and b) 
chronic administration results in no or only a slight increase in replicative DNA synthesis. 
Furthermore, mitogen-induced liver cell hyperplasia is less predisposed to become carcinogenic and 
several potent mitogens without a peroxisomal proliferative effect are not carcinogenic (15). 
5. Conclusion 
The NOEL for DEHA in the rat, based on the peroxisomal effects in the liver, as measured by 
biochemical parameters and electromicroscopic analysis in this sensitive species, is around 100 mg/kg 
b.w. Bearing in mind the lack of genotoxic activity in all but one mutagenicity assay using several 
endpoints, the large margin between the doses of DEHA necessary to induce hepatic rumours only in 
mice (1715-3570 mg/kg b.w.) and those inducing hepatic peroxisomal activity (>100 mg/kg b.w.), as 
well as the evidence for a threshold for inducing hepatic peroxisomal activity enables the Committee 
to conclude that the very small intakes of DEHA from its uses in food contact materials would not pose 
any carcinogenic hazard for man. 
Foetotoxicity occurred in a teratogenicity study in rats at 110 mg/kg b.w. The NOEL was 30 mg/kg b.w. 
The Committee therefore used a safety factor of 100 to establish a TDI for DEHA of 0.3 mg/kg b.w. 
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1. Background 
Chemical hydrolysates of vegetable proteins are commonly used as seasonings to improve the flavour 
of certain foods. Hydrolysis is usually achieved by treatment of crude proteins with hydrochloric 
acid. During this process, hydrochloric acid also interacts with glycerol released from vegetable fat 
yielding a number of chlorinated products, including 3-monochloro-propane-l,2-diol (3-MCPD). 
3-MCPD is not the sole chloropropanol formed during the technological process currently used to 
produce hydrolysed vegetable protein. At its 62
nt* meeting (15 April 1988) the Committee examined 
l,3-dichloro-2-propanol (DCP). Long-term toxicity/carcinogenicity studies in rats indicated a 
carcinogenic potential for this substance. 
At its 74th meeting (28/29 June 1990) the Committee evaluated the contamination of hydrolysed plant 
proteins with 3-MCPD. 
At that time, only limited information from a range of studies on 3-MCPD was available for 
assessment, including data on metabolism, acute toxicity, short-term and long-term toxicity, 
reproductive toxicity and genotoxicity. Although certain metabolites of 3-MCPD were identified, the 
metabolism of 3-MCPD was not yet fully understood. The data lacked well described toxicokinetic 
and mass balance studies. The available information, however, suggested that 3-MCPD was rapidly 
absorbed and circulated, crossed biological barriers and was distributed into many tissues and organs. 
No information on short-term toxicity in non-rodent species was available. Chronic toxicity and 
carcinogenicity data on 3-MCPD were scarce. Reproduction studies focused mainly on the specific 
adverse effects of 3-MCPD on male fertility. The teratogenic potential of 3-MCPD had not been 
investigated. The results of special studies on genotoxicity remained inconclusive, although the 
substance was genotoxic in certain in vitro test systems. 
It was not possible to establish an exposure limit for human consumers of 3-MCPD on the basis of this 
information. However, the Committee took into account that 3-MCPD was nephrotoxic, possessed an 
inhibitory effect on male fertility and showed genotoxic activity in some in vitro assays. 
The Committee concluded that: 
"Based upon available analytical data, the Committee recognised, that the contents of 3-
chloro-l^-propanediol
1 (monochloro-propane-diol, MCPD) are highly variable among 
different hydrolysed vegetable protein preparations. 
1 3-monochloro-propane-l,2-diol or 3-MCPD 
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Due to the present knowledge of toxicity of the compound and the information from the 
industry on present technology allowing contents below 10 mg MCPD per kg hydrolysed 
vegetable protein, the Committee is of the opinion that products with a higher content 
than this should be considered not acceptable." 
In the meantime, a carcinogenicity study in rats has been completed. In this study, groups of 50 male 
and 50 female Fisher F 344 rats were exposed to drinking water containing 3-MCPD dissolved in tap 
water for 104 weeks. Average daily intakes of 1.1, 5.2, and 28.3 mg 3-MCPD/kg body weight for the 
males, and 1.4, 7.0 and 35.3 for the females were calculated on the basis of body weights, liquid 
consumption and drinking water analyses. 
Treatment with 3-MCPD was accompanied by a dose-dependent increase in the incidence of tumours in 
the kidneys of animals of both sexes and in the testes, mammary and preputial glands of males. These 
results led to reconsideration of the above recommendation. 
It had been argued that the kidney tumours were secondary to sustained organ toxicity. Furthermore, 
hormonal disturbances had been suggested to explain the appearance of tumours in the testes and 
mammary glands. However, no convincing experimental evidence was provided to support this 
assumption. It was also reported that attempts had been made to estimate the virtually safe dose of 
3-MCPD by using log-probit extrapolation methods. However, the inaccurate dosing might render any 
attempt to quantitatively extrapolate the carcinogenicity data meaningless. The Committee is 
concerned by the large uncertainty of the dosing levels of the test substance during this study. As 
shown by the figures quoted in the footnote
2, within-dose group variations of up to a factor of eight 
were reported for the 3-MCPD concentration. 
2. Conclusion 
The Committee noted that several of the above described gaps of information had not been filled since 
it's first evaluation of 3-MCrD. However, based on the results of the recent carcinogenicity study and 
other available data, the Committee is now of the opinion that there is sufficient evidence for 
carcinogenicity of 3-MCPD in rats. In addition, 3-MCPD is mutagenic in the Ames test causing base 
pair substitutions in S. typh. TA 1535, positive in the mouse lymphoma TK locus assay, and possibly 
the Chinese hamster V79 HPRT test in vitro, and causes sister chromatid exchanges in V79 cells. In 
view of the clearly demonstrated in vitro genotoxicity and the tumorigenic effect in rats, 3-MCPD 
must be regarded as a genotoxic carcinogen. It also causes malignant transformations in mouse 
fibroblasts. While the role of nephrotoxicity and hormonally mediated effects of 3-MCPD cannot be 
2 Results of drinking water analysis indicated that the concentrations administered ranged between 
0 and 22 ppm (control group), 0 and 89 ppm (low-dose group), 58 and 495 ppm (intermediate-dose 
group) and 244 and 626 ppm (high-dose group). The report states that the limit of detection of the 
analytical method applied was in the order of 10 ppm. 
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ruled out, conclusive evidence for the significance of such (secondary) hormonal mechanisms has not 
been provided. A safe threshold dose cannot be determined and 3-MCPD should be considered as an 
undesirable contaminant in food. Therefore residues of 3-MCPD in food products should be 
undetectable by the most sensitive analytical method
3. 
Given the level of usage of hydrolysed plant proteins and the difficulty of determining 3-MCPD at 
the lower concentrations encountered in food products containing them, the Committee recommends 
that the presence of this substance be routinely controlled by analysis of the hydrolysed plant 
proteins themselves and that all efforts should be undertaken to develop technological methods 
leading to products not containing chlorinated propanols. 
In view of the importance of controlling the presence of the substance in imported foods, the 
Committee further recommends that efforts be made to develop analytical methods allowing 
detection of 3-MCPD in finished foodstuffs at the levels likely to be encountered from use of 
contaminated hydrolysed plant protein. 
3 The Committee notes that, at present, methods using gas chromatography and electron capture 
detection, can achieve a limit of detection of 0.05 mg/kg in liquid hydrolysed plant proteins 
containing 40% dry matter. 
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1. Terms of reference 
The Committee has been entrusted with the task of carrying out an evaluation of the use of 
polyethyleneglycol 6000 (PEG 6000) in preparations for sweetener-based sodas. 
2. Background and discussion 
These preparations, which are supplied in the form of tablets notably containing around 3% of PEG 
6000, are designed to produce when dissolved in water a soda-type beverage. In principle, their use is 
limited and they are not for the consumption of young children. 
PEG 6000 is an excipient defined in the European pharmacopoeia, under the name of macrogol 6000, as 
a mixture of polymers with the general formula H(OCH2-CH2)nOH corresponding approximately to 
a molecular weight of 6000. The European pharmacopoeia stipulates the purity criteria with which 
this mixture of polymers must comply (1). 
Most of the studies which have been carried out in this field are relatively old, and there is little 
extant information available on PEG 6000. However, it is generally acknowledged that the 
gastrointestinal resorption of polyethyleneglycols and their toxicity are inversely proportionate to 
their molecular weight (2). 
PEG 4000, a polyethyleneglycol with a lower molecular weight than that of PEG 6000, has been 
administered for 12 months to a dog without any occurrence of side effects. PEG 4000 is used in the 
clinical field as a non-absorbable marker. A 90-day study on the rat has revealed the innocuousness of 
PEG 6000 which, moreover, is used without any known toxic effects as an excipient in certain 
pharmaceutical preparations (3). 
3. Conclusion 
Taking into account its low resorption, the absence of known toxic manifestations and the limited 
exposure which could result from the recommended use, PEG 6000 (polyethyleneglycol 6000), as 
defined in the European pharmacopoeia, may be considered as acceptable for the limited requested 
use, i.e. as an excipient of sweetener-based tablets for the preparation of sodas. 
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36 Reports of the Scientific Committee for Food (Thirty-sixth series) OPINION ON THE FOOD SAFETY IMPLICATIONS OF SURVEILLANCE SYSTEMS 
EMPLOYING NEUTRON SCANNING (INTERROGATION) DEVICES 
EXPRESSED ON 3 MARCH 1995 
1. Terms of reference 
The SCF has been requested to consider whether the use of neutron scanning devices, and pulsed fast 
neutron analysis, (PFNA) in particular, would cause foodstuffs exposed to this type of interrogative 
irradiation to become a hazard to the health of the consumer. 
2. Background 
Cargo surveying systems presently used for baggage, luggage and freight inspection at airports, where 
security assurance is necessary, hitherto employed ionising radiation, commonly in the form of X-rays 
or of thermal neutron activation (TNA) systems, operating at low radiation doses or low mean neutron 
energies. UK regulations recognised the established safe use of such devices providing they impart a 
maximum radiation dose not greater than 0.5 Gy to the inspected material. The more recent need for 
non-invasive detection procedures for explosives or other contraband in large containers, heavy goods 
trucks and railway cars necessitates the employment of more powerful radiation interrogation 
systems. Because these large objects may also contain foods in transport, reassurance is now needed 
that such novel scanning procedures do not produce in the exposed foodstuffs any radiolytte products 
and induced radioactivity potentially deleterious to the consumer as well as the foodstuffs. The major 
concerns relate to the levels of induced radioactivity, the radiochemical changes, the likelihood of 
creating toxic effects, and the possible nutritional and organoleptic changes in the exposed food. The 
Committee was provided with a report on neutron-induced activation of food (1), a report on food 
safety effects of inspection by SAIC pulsed fast neutron analysis explosive detection system (2), and a 
paper on the irradiation of food and the induction of radioactivity (3) as background information. 
3. Discussion 
TNA systems use slow neutrons at mean energies much below 5 MeV and impart radiation doses well 
below 0.5 Gy, the present UK limit for exemption from irradiation control regulations, to the material 
inspected. X-ray scanning devices are limited to operate at a maximum energy of 10 MeV and at 
maximum dose levels of 0.5 Gy. The PFNA systems have a far better penetrating power but require low 
Reports of the Scientific Committee for Food (Thirty-sixth series) 37 3 MARCH 1995 NEUTRON SCANNING (INTERROGATION) DEVICES 
intensity neutron beams of high-energy neutrons, around 8 MeV, with an incident fast neutron flux of 
5.0xl0
5 neutrons cm'V
1. In the worst case, a 5 minute directed search of a suspicious cargo, this would 
impart to any foodstuff present a radiation dose of about 0.0063 Gy ( i.e. less than 0.01 Gy)(*). 
The physical basis for the PENA is the stimulation by fast high-energy neutrons of the emission of 
gamma-rays characteristic of the different chemical elements in the irradiated target. These 
gamma-rays can be detected and thus identify the elements present in the target. Particular attention 
is given to the gamma-ray emissions from O, C and N atoms, because these elements, usually present in 
organic explosives at characteristic concentrations, yield distinct distribution patterns easily 
distinguishable from the patterns produced by foodstuffs. The scanning process involves the vertical 
sweeping by a collimated neutron beam, 20 cm in transverse diameter, of a horizontally moving 
container. The emitted gamma-rays are registered by an array of detectors linked to an appropriate 
computer system and provide a two-dimensional location of the elements emitting gamma-rays. Exact 
determination of the time of detection then gives information on the third spatial dimension along 
the direction of the neutron beam within the interrogated target. The resulting three-dimensional 
element distribution picture then indicates the presence and position of the suspected explosives mass 
within the scanned container. A normal fast scan of a container results in the neutron beam impinging 
on any spatial position for a maximum of 1 second. For directed search studies of suspicious locations 
from 10 s to a maximum of 5 min may be needed. Not more than 1% of a container is expected to undergo 
directed search. 
The radiation effects of neutrons differ from those of ionising radiation, which latter removes 
electrons from irradiated atoms. Neutrons undergo elastic collisions with atomic nuclei, thereby being 
slowed and imparting recoil energy to the colliding atomic nuclei, which is then dissipated by 
interaction with electrons to yield radiochemical reactions products. Most neutrons thermalise (reach 
thermal equilibrium) in hydrogen-rich media by repeated collisions with protons. In other media 
neutrons are also captured by the atomic nuclei and then undergo nuclear reactions. Slow thermal 
neutrons are more effective in undergoing reactions with atomic nuclei than fast neutrons, particularly 
if neutron capture is involved. Neutron capture increases the atomic weight by 1. Fast neutrons tend to 
alter the atomic number of the colliding nucleus, thus creating a different chemical element. Neutrons 
therefore have a greater propensity to induce radioactivity in the scanned material and do not form 
any significant amounts of radiolytic products. The probabilities for the occurrence of the various 
nuclear reactions are tabulated extensively in the literature as nuclear cross sections for neutrons of 
different energies. 
(*) This dose is calculated from the effective equivalent dose of 21 mrem received by a man exposed 




1- As 1 mrem = 0.01 mSv, a 5 minute (300 s) exposure equals 21x300x0.01 = 0.63 mSv = 
0.063 Sv. For irradiation by neutrons a dose of 10 Sv = lGy, hence 0.063 Sv = 0.063x1ο
4 = 0.0063 Gy. 
Effective equivalent doses are measured in Sv (Sieverts) and represent the biological effectiveness 
of the radiation. They are calculated from the formula GyxF, where F depends on the type of 
radiation, being 1 for X-rays, ß-rays, hard gamma-rays, 20 for alpha-rays and 2-10 for neutron-
rays. 
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The induced radioactivities for a large number of significant elements in food and the resultant 
effective equivalent doses to consumers of such neutron-interrogated food can be calculated, assuming a 
maximum absorbed dose of 0.5 Gy from irradiation with neutrons of energies 1,2,5, 8 and 14 MeV, and 
also assuming delay times in measuring the radioactivity of 5 min, 1 hr, 8 hrs, 1 day, 1 week and 1 
month. The physical characteristics of the scanning neutron beam are not important for assessing the 
health risk to the consumer but the levels of radioactivity induced in the neutron-irradiated food and 
the effective equivalent radiation dose received when such food is ingested. 
In order to calculate these parameters several paradigms were proposed. Apart from 17 specific foods, 
a theoretical food (mccf) containing the maximum credible concentrations of 81 key elements, and a 
theoretical reference food (rf), composed of 47 elements in concentrations based on their daily balance 
in the diet consumed by a "reference" man, were considered. Three configurations of containers were 
also considered: a semi-infinite slab, 1 kg food contained in a 20 kg luggage, and a 2 m high pallet of 
food. Using standard nuclear physics programmes and information in nuclear data banks the resulting 
neutron transport spectra and radioisotope inventories were calculated for these 19 foods considered 
exposed to neutron interrogation. 
Although gross radioactivity is generally easier to measure than the amounts of individual 
radionuclides, this is a less important parameter in determining the radiological significance of the 
induced activities than the radioactive half-life and the radiation dose/unit activity intake of the 
various radionuclides present in the food. 
Experimental methods to detect the additional induced radioactivity would require the application 
of much higher nuclear irradiation doses than is proposed in the PFNA screening procedure. Moreover, 
at the proposed maximum PFNA irradiation dose level of 0.01 Gy it is virtually impossible and 
extremely difficult to measure either the induced additional radioactivity or any radiolytte products 
by current analytical techniques or long-lived radicals by ESR. Therefore any changes in food exposed 
to neutron interrogation will be essentially undetectable and thus negligible. 
The only way to obtain actual values of the above-mentioned parameters for the assessment of the 
radiological risk from exposure by the ingestion of PFNA-screened food is the use of the well 
established, verified and routinely applied calculational methods discussed in the background 
information supplied to the SCF. 
Under the conditions of assuming the worst scenario described above and an irradiation dose of 0.5 Gy, 
the calculations show that the radioactivity of the theoretical (mccf) food does not fall below the 
0.4 Bq g"
1 exemption limit for control of radioactive materials under the 1960 UK regulations even 
after a post-scanning delay of 1 month. This is largely due to its high K-content and the 
correspondingly high naturally occurring radioactivity. The activity of the theoretical rf food falls 
below the 0.4 Bq g"
1 exemption limit in less than 1 week. The activity levels of the 17 specified foods 
vary after 1 week post-scanning from almost the mccf value to several orders of magnitude less, 
depending on the initial elemental composition, and are generally below the 0.4 Bq g"
1 exemption 
limit. 
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In estimating the effective equivalent dose to members of the public from exposure through ingestioj 
of neutron-scanned food comparison should also be made with the international limit (ICPR) of 1 mSi 
per year averaged over a lifetime or with the more recent recommendation (NRPB) of a dosi 
constraint, applied to a single source, of 0.3 mSv per year or with the advice (ACINF-UK) tha 
irradiated foodstuffs with an activity content of less than 0.4 Bq g"
1 giving rise to individua 
exposures of less than 5 pSv (0.005 mSv) per year should not be of concern to regulatory authorities 
Furthermore, it has to be remembered that there will be always some delay between irradiation anc 
consumption with a realistic minimum of 5 minutes. Also such scanned food represents only a smal 
fraction of the daily diet. 
Assuming prompt consumption of 1 kg of 5 minute-cooled neutron-scanned mccf food consumers would be 
subject to an exposure dose of 100 uSv/year, after 1 day-cooling it would be about 20 uSv/year and 
after 1 month-coolingabout 10 pSv/year. The no-regulatory-concem dose of 5 μ5ν/γβατ would be 
reached by ingestion of 50 g of 5 minute-cooled or 500 g of 1 month-cooled mccf food. 
Assuming prompt consumption of 1 kg of 5 minute-cooled neutron-scanned rf food consumers would be 
subject to an exposure dose of 2-5 pSv/year depending on the MeV of the scanning beam. After 1 day-
cooling the exposure dose would be about 0.9 pSv/year and after 1 month-cooling about 0.2 pSv/year. 
For the 17 specific foods a wide range of results arises but for most foods, after likely delays before 
consumption, exposure doses following ingestion of 1 kg neutron-scanned food would be below 1 
uSv/year. Doses above 5pSv/year could only occur with very few foods with a high initial Na, Cl, P, 
Κ, Ο, Ν and S content and which have been regularly neutron-scanned and marketed consistently to 
regular consumers. 
The natural radioactivity levels in the diet are about 0.1 Bq g"
1 and thus lower than those in foods 
immediately after neutron-scanning. However the annual individual exposure doses arising from 
consumption of unirradiated food are of the order of 300 pSv, so that the contribution of less than 
5 uSv/year from the likely small percentage in the total diet of neutron-scanned food is negligible. It 
should be noted that the total individual exposure doses due to natural background radioactivity are 
of the order of 2000 uSv (200 mrem) per year. 
4. Conclusions 
On the basis of the above information the SCF has concluded, that surveillance devices using neutron 
scanning, in particular PFNA systems operating at up to 14 MeV, which during interrogation do not 
impart to foodstuffs radiation doses greater than 0.01 Gy, raise no safety concerns with regard to the 
negligible induced additional radioactivity, radiolytic products, their toxicity, nutritional and 
organoleptic properties of the neutron-interrogated foodstuffs. The estimated maximum effective 
equivalent radiation dose to the individual consumer would amount to less than 5 p£>v from natural 
background radiation. However, in order to allay any consumer concerns it would be desirable to 
confirm the theoretically calculated induced radioactivity levels by testing food from a container 
which has been subjected to neutron scanning by a PFNA system for any induced radioactivity. A 
procedure should also be developed, which ensures that the same food items are not exposed 
repeatedly to neutron scanning, as this opinion of the committee applies only to foods which have 
been subjected to a single exposure of PFNA scanning. 
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EXPRESSED ON 3 MARCH 1995 
1. Terms of reference 
To provide clarification of the opinion expressed on iso-ascorbic acid (erythorbic acid) on 19 October 
1990 (Scientific Committee for Food, Twenty-sixth Series of Reports). 
2. Background 
The Scientific Committee for Food has evaluated the safety in use of iso-ascorbic acid on two previous 
occasions. In its opinion of September 1984, the Committee concluded that the data then available 
were inadequate for full toxicological evaluation of the substance and, further, that the possibility of 
competitive interference with the absorption and distribution of ascorbic acid might be of significance 
for individuals with borderline intakes of this vitamin. On that occasion, the Committee was of the 
opinion that the use of iso-ascorbic acid in food and drink was not acceptable and did not establish an 
ADI (Scientific Committee for Food, Twenty-second Series of Reports). Subsequently, in its opinion of 
19 October 1990, on the basis of the results of a long-term study in rats and the satisfactory agreement 
of those findings with reported human nutritional experience, the Committee established an ADI of 6 
mg/kg bw (Scientific Committee for Food, Twenty-sixth Series of Reports). The rationale for that 
conclusion was not presented in extenso in its published report. 
In response to the request from the Commission to clarify its opinion on iso-ascorbic acid, the 
Committee sets out in the following text the reasoning supporting its conclusions of 19 October 1990 and 
also takes the opportunity to review its conclusions in the light of the recently adopted European 
Parliament and Council Directive 95/2/EC concerning food additives other than colours and 
sweeteners which establishes for the first time at European Union level provision for the use of iso-
ascorbic acid in food. 
3. Discussion and conclusions 
Rats, mice, hamsters and rabbits lack the active carrier-mediated absorption mechanism present in 
guineapigs and man. Intestinal absorption of iso-ascorbic acid has been shown to be less efficient in 
rodents compared to guineapigs and man. Retention of iso-ascorbic acid in the tissues and reabsorption 
in the kidneys is also poor, thus leading to its rapid elimination in the urine. Iso-ascorbic acid is 
therefore regarded as having low antiscorbutic activity. The evidence regarding iso-ascorbic acid 
interference with the ascorbic acid tissue stores or absorption is somewhat contradictory. Normal 
dietary intake from the presently suggested uses are not likely to lead to any significant deficiency in 
ascorbic acid. Only concentrations of iso-ascorbic acid at least an order of magnitude higher than 
those of ascorbic acid are likely to interfere significantly with ascorbic acid uptake. Human studies 
showed that daily doses of 600 mg had no adverse effects on ascorbic acid repletion in volunteers 
depleted of ascorbic acid. 
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The metabolism of iso-ascorbic acid has not been studied in detail but appears, at least qualitatively 
to be similar to that of ascorbic acid. Although formal multigeneration reproduction studies have not 
been carried out, other studies show that at least male reproductive function is not affected by orally 
administered iso-ascorbic acid. Iso-ascorbic acid is neither teratogenic nor genotoxic. 
Despite the comparatively poor absorption of ingested iso-ascorbic acid by rodents, the doses 
employed in the available life-span studies in mice (Inai et al., 1989) are likely to have resulted in 
plasma levels of iso-ascorbic acid similar to those found in human volunteers given comparatively 
excessive doses for a prolonged period. In a 7 months study in mice, a dose of 15 g/kg b.w. gave plasma 
levels of 25 mg/1 (Tsao & Salimi, 1983). In the life-span study in mice, no plasma levels were 
measured but the dose used was 3.3-7 g/kg b.w. In a study in human female volunteers, a dose of 10 
mg/kg b.w. gave plasma levels of 3.5 mg/1. Normal dietary intakes, based on present technological 
uses, are around 0.13 mg/kg b.w. In the life-span rat study used to set the ADI doses of 0.625-1.25 g/kg 
b.w. were given but no plasma levels were measured. Therefore, at least one rodent study probably 
achieved adequate blood levels. Although the available life-span studies in mice and rats are 
inadequate in several respects in the light of modern requirements they did not produce any evidence 
for carcinogenicity or specific chronic toxic effects. 
Overall, despite some deficiencies in the database, the Committee considered the use of iso-ascorbic 
acid to be acceptable because (i) although the metabolism of iso-ascorbic acid is not identical to 
ascorbic acid, it is similar, (ii) although rodents are less efficient at absorbing iso-ascorbic acid, there 
is some absorption in rats and mice (the species used in the toxicity studies) and (iii) no adverse effects 
have been reported from human exposure to date. As the NEL in the rat study was found to be lower 
than the minimal effect dose level in the mouse study, the ADI, previously established on the basis of 
the rat study, was confirmed. 
ADI for man: 6 mg/kg b.w. 
Current uses Usted in the Directive (95/2/EC) are likely to result in dietary intakes well below the 
ADI. The Committee would like to be informed if new uses are being proposed which are likely to 
lead to intakes persistently exceeding the ADI. 
The data reviewed during the course of this evaluation are summarised in the annex to this text. 
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D-ISOASCORBIC (ERYTHORBIC) ACID AND ITS SODIUM, POTASSIUM AND 
CALCIUM SALTS 
Background 








H — C — OH 
CH2OH 
It is manufactured from Ca-2-keto-d-gluconate by a multistep process. The commercial product is 
crystalline IAA or Na-IAA and is cheaper than ascorbic acid (AA). 
It functions technologically as: 
a) antioxidant to stabilise colour and flavour in fresh, frozen and canned fruits, to stabilise 
betacyanins, to prevent off-flavours in citrus flavoured carbonated drinks, beer, minced-fish. 
b) accelerator of nitrite cure for meats, for better shelf life (colour, flavour), reduction in residual 
nitrite, inhibition of nitrosamine formation. 
Use levels:  fruit juices 







IAA and Na-IAA are permitted food additives in USA, Canada, Japan, Australia, New Zealand, 
Eastern Europe and some South American states either in fruit juices, fruits or cured meat products. In 
the EU their use is prohibited by the Antioxidants Directive and the Antioxidants in Food 
Regulations. IAA is also used in certain wines which cannot therefore be imported into the European 
Community. 
A simple, quick and reliable analytical method distinguishes between AA and IAA (Hoffman, B. 
1980). 
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IAA and Na-IAA were evaluated by JECFA in 1961,1973 and 1990. In the earlier evaluation an ADI of 
5 mg/kg b.w. was established by that committee on the basis of a long-term study in rats (WHO, 1974) 
but this was changed to an ADI "not specified" (WHO, 1991) on the basis of new long-term toxicity 
and carcinogenicity studies in rats and mice as well as studies on the metabolic and nutritional 
interactions of IAA with AA including human studies. 
Additional information has become available since that time which permits a re-appraisal of these 
substances. 
The SCF evaluated IAA in 1990 and 1992 and established an ADI of 6 mg/kg b.w. (SCF 1990 and 1992). 
Biological data 
Biochemical aspects 
Absorption, metabolism, distribution, excretion: 
Many studies have been carried out in guineapigs which lack L-gulono-lactono-oxidase and cannot 
synthesise AA similar to man and the primates. Rats, hamsters and rabbits synthesise AA and do not 
appear to have an active transport mechanism for AA but absorb it and IAA by passive diffusion. 
Absorption of IAA from the gastrointestinal tract in man and guineapigs proceeds readily though less 
efficiently by the same active transport mechanism as for AA (Gould B.S.,1948; FASEB Report 1979; 
Hughes, R.E. & Jones, P.R. 1970). Comparison of plasma levels of IAA following prolonged 
administration orally to mice (Tsao, CS. & Salimi, S.L. 1983) with the study in human volunteers 
(Sauberlich, H.E. et al, 1989) demonstrates similar plasma levels despite an order of magnitude lower 
intake in the human volunteers. Possibly the active carrier-mediated mechanism in man causes 
greater gut absorption and/or tubular reabsorption. The transport mechanism is located in the brush 
border membrane vesicles (Toggenburger, G. et al, 1979). Transport of L-AA and D-IAA is Na
+-
dependent, electro-neutral and saturable. It is competitive and therefore potentially able to reduce 
AA uptake from the intestine, although IAA is a poorer substrate (Siliprandi, L. et al, 1979). Intact 
gut segments show a 16% decrease in AA influx if IAA is present at 10 times the AA concentration 
(Mellors, A.J. et al, 1977). However simultaneous oral administration of 1-C
14-IAA and 6-H
3-AA to 
guineapigs resulted in similar specific activities in the portal blood for 3.5 hours (Hornig, D. 1977). 
The metabolism of IAA has been little investigated. It probably follows the same pathways as AA. 
Rats fed IAA excreted dehydro-IAA (Fukushima, S. et al 1986) but no IAA-2-sulphate (Baker, E.M. et 
al 1973) in the urine. The final metabolites of IAA are probably CO
2, oxalic acid and C4- and 
C5-derivatives. 
l-C
14-labelled IAA administered orally or i.p. to guineapigs was almost completely cleared from the 
body within 24 h. After i.p. administration over 75% appeared in the urine, 20% was exhaled, 3% 
was in the faeces. After oral administration some 54% was exhaled, 30% appeared in the urine and 
4% in the faeces. Trace amounts (less than 1%) were found in the organs, chiefly liver, lung and 
kidneys (Hornig, D. 1975). Guineapigs given 40 mg/day for 2 months excreted at that time 1.9% of the 
ingested dose in their urine (Pelletier, O. 1969). 
Dogs given 5 g Na-IAA excreted 19% within 24 h (Rivers, J.M. et al 1963). Rats excreted in their urine 
10 times more C
14-labelled IAA compared to AA (Baker, E.M. et al 1973). However rats given 5% IAA 
in their diet only excreted twice as much as those given AA, only 5-10% of the excreted material was 
unchanged IAA (Fukushima, S. et al 1984). 
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In human subjects an oral dose of 300 mg IAA did not affect the urinary AA level (Kadin, H. 1959). 
Loading tests on 6 volunteers with 165 or 300 mg IAA showed similar blood levels over 3 hours to those 
obtained with AA. Balance studies showed that 50-70% of the IAA test load compared to 15% of AA 
were excreted within 24 hours. Excretion of IAA was more rapid and more complete suggesting little 
renal tubular resorption and no displacement of AA (Wang, M.M. 1962). Four males, partially 
depleted of AA were then given 50 mg IAA daily for 2 weeks, followed by 100 mg daily for 2 weeks. 
While all AA concentrations continued to fall throughout the 4 weeks, the urinary excretion of IAA 
increased considerably. A loading dose of 300 mg did not raise the white cell AA level, 50-60% of the 
load appearing in the urine. The fate of the retained portion is not known nor the function of the 
dehydro-IAA. White cell uptake appeared to be stereospecific (Rivers, J.M., 1963). 
Tissues abstract IAA easily from the blood and reach 60-79% of the AA level but retain IAA less 
strongly (Hughes, RE. et al, 1969; Hughes, RE. et al, 1970). Oral graded doses of either AA or IAA, 
given to guineapigs over 16 days, produced detectable tissue levels of IAA only with doses of 20 or 100 
mg/day. Less IAA was retained in the tissues compared to equivalent AA loading (Suzuki, E., et al 
1988). IAA administered orally simultaneously with AA impaired AA uptake by guineapig tissues at 
doses of 200 mg/kg and above, thus reducing AA storage and bioavailability up to 50% in some organs 
(Hornig D. et al, 1974). 
Transfer of IAA across membranes into the aqueous humour of the guineapig eye uses the same 
saturable transport mechanism as AA, although the affinity of IAA is smaller (Linnér, E. et al, 1969). 
The transport mechanism for crossing the blood/brain barrier is similarly stereospecific, IAA having 
a lower affinity for the carrier than AA (Spector, R. et al, 1974). In vitro IAA also inhibits the 
accumulation of C
14-labelled AA in the isolated rabbit choroid plexus (Shibata, M.A. et al., 1989). 
Similar competitive inhibition of AA transport by IAA but with lower carrier affinity was noted for 
guineapig and rabbit ciliary bodies (Becker, B. 1967), cat retinal pigment cells (Khatami, M. et al, 
1986), human placental microvillous membrane vesicles (Iioka, H. et al 1987) and rabbit ciliary 
epithelium (Chu, T.C., 1988). When tissue concentrations were examined after 9 days loading with 
IAA or AA, followed by 4 days depletion diet, the final tissue levels of IAA were much below those of 
AA despite higher doses of IAA. Thus the turnover rate of IAA was 4-5 times higher, the half-life 
correspondingly 4-5 times shorter (Pelletier, O. 1969). 
IAA is rapidly eliminated in the urine and thus less toxic for man than AA (Gould B.S. 1948). Renal 
tubular reabsorption of IAA from the glomerular filtrate probably uses the same stereospecific, energy 
requiring transport system as for AA but is less efficient. IAA inhibits in vitro AA uptake into kidney 
cortex vesicles. IAA can therefore compete with and reduce AA reabsorption (Toggenburger, G. et al 
1979). However dogs given a single i.v. dose of AA or IAA showed nearly identical plasma half-lives 
indicating that elimination and reabsorption had the same rate rather than being better for AA 
(Robinson, R. et al 1956). Daily oral doses of 600 mg IAA in adult women gave the same steady state 
plasma concentration as 60 mg AA (Sauberlich, H.E. et al 1989). 
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Vitamin C activity 
In vivo IAA has from l/20th to l/40th of the antiscorbutic activity of AA. In one study, however, no 
such activity was seen (Reiff, J.S. et al 1959). Guineapigs on a scorbutogenic diet survived for 100 days 
on supplementary 10 mg IAA/day though weight gain was slightly reduced. Supplementary 1-2 mg 
AA/day produced full growth (Fabianek, J. et al 1967). Continuous dosage in drinking water or large 
daily doses adequately relieved or protected against scurvy. Single low oral doses showed little 
antiscorbutic effect because of the less efficient absorption of IAA in the gut and poor tissue storage 
(Hughes, R.E. et al 1970). AA-depleted guineapigs received 2 mg AA or 40 mg IAA daily for 2 months 
with full restoration of growth. Tissue levels of IAA were only about 1/2 of those of AA. This 
reduction in physiological activity in vivo may be apparent rather than real because of the less 
efficient uptake and faster urinary loss (Pelletier, O. et al 1969). Guineapigs on scorbutogenic diet kept 
well on 0.1% IAA in drinking water. IAA-pretreated animals were depleted twice as fast as 
AA-pretreated animals (Hughes, R.E. 1969; Hughes, R.E. 1971). The relative potencies of IAA and 
AA were compared in female guineapigs after a 6-day depletion diet. 100 mg IAA/day, 10 mg 
AA/day, 100 mg IAA + 0.5 mg AA/day or 100 mg IAA + 5 mg AA/day were then given for 9 weeks. 
Growth, SAP levels, collagen formation after wounding and tooth structure were normal. The effect of 
IAA was additive to subminimal AA levels and there was no competitive inhibition (Goldman, H.M. 
et al 1981). In vivo CC
14-induced lipid peroxidation, as shown by pentane and ethane exhalation, was 
inhibited equally for 4 hours in deficient guineapigs by i.p. administered 75 mg IAA or AA as 
antioxidants (Kunert, K.J. et al 1983). IAA and AA were equally potent cofactors in vitro in promoting 
proline hydroxylation in cell-free systems (Kurata, T. et al 1987; Kutnink, M.A. 1969). IAA and AA 
had the same effects on hepatic microsomal UDP-glucuronyltransferase (Neumann, CM. et al 1988). 
To achieve equal potency in stimulating collagen synthesis in incubated intact cells required 8-10 
times higher concentrations of IAA at low concentrations but equal concentrations of IAA and AA at 
250 |iM (Murad, S. et al 1981). 
Interaction of IAA and AA 
The possibility of an anti-vitamin C effect due to competition in the transport mechanism was 
examined in guineapigs, mice and human volunteers Tissue concentrations in guineapigs receiving a 
semipurified diet plus either 0.1% AA or 0.1% AA + 2% IAA for 1 week showed deposition of IAA in 
organs with replacement of 1/2 of the AA. If followed by a treatment period with AA alone there was 
rapid loss of IAA (Pelletier, O. 1969). The effect of IAA on the turnover rate of l-C
14-labelled AA, 
given as pretreatment to guineapigs on either scorbutic diet or with additional 0.1% AA or 2% IAA 
showed that the disappearance of labelled AA from brain, liver, heart, kidney, adrenals and spleen 
was accelerated more by IAA than AA for 6 days and the reverse for a further 4 days. IAA therefore 
increases AA turnover and does not spare AA (Pelletier, O. 1969). Guineapigs were given daily doses 
of 0, 20, 50,100 or 400 mg IAA + 20 mg AA/day for 3 days and then loaded with oral single doses of 
l-C
14-labelled AA. Tissue distribution after 6 hours showed a decreased C
1
4 retention the higher the 
IAA dose (50 mg and higher) (Hornig, D. 1975). As the absorption rates of IAA and AA by guineapig 
gut are similar without competitive inhibition the reduction in tissue-AA could be due to faster 
metabolism and renal elimination. Using single oral doses of l-C
14-labelled AA in guineapigs on 
deficient diet for 12 days and then for 16 days either 5 mg AA/kg b.w., 50 mg IAA/kg b.w. and 50 mg 
IAA + 5 mg AA/kg b.w. produced body weight depression in animals given IAA + AA or IAA alone. 
Respiratory C
14-C02 rose from 43% (AA) to 48% (IAA+AA) to 50% (IAA); urinary and faecal 
excretion were similar in the 3 groups. Hence IAA accelerated AA metabolism with a reduced 
half-life from 97 to 50 h. The body pool of AA was reduced by 30% by IAA + AA (Hornig, D. 1976). 
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IAA also stimulated hepatic decarboxylase (Hornig, D. 1977). Measuring tissue levels of AA and IAA 
by HPLC in guineapigs given either 0 or 5 mg AA/day, 100 mg IAA/day or 100 mg IAA + 5 mg AA/day 
showed lower tissue contents in animals given the mixture. Hepatic AA of IAA animals was the same 
as in the deficient animals and the disappearance rate of AA from tissues of IAA animals was the 
same as in deficient animals. Hence no increase in catabolism was noted but interference with uptake 
or alternatively there was an accelerated degradation of newly absorbed AA only (Arakawa, N. 
1986). 
Guineapigs were given a diet with 5 or 1 mg AA/day plus 0,1, 5, 20 or 100 mg IAA/day. 100 mg IAA 
reduced tissue levels of the 5 mg AA/day animals but not of the 1 mg AA/day animals (Suzuki, E. 
1988). 6 groups of guineapigs were given supplements of 1 mg AA + 1 mg IAA, 1 mg AA + 20 mg IAA, 5 
mg AA + 1 or 5 or 20 or 100 mg IAA for 16 days. Body weights were similar in all groups. Liver AA of 
the 5 + 100 group was 50% of that of the 5 group. The activities of hepatic aniline hydroxylase, acid 
phosphatese, SAP, cytochrome P-450 were unaffected. At 1 mg AA the hepatic acid phosphatase and 
aniline hydroxylase activity were lower and restored in the 1+20 group (Suzuki, E. 1988). Groups of 4 
male guineapigs were given 5 mg AA/day, 100 mg IAA/day or 100 mg IAA + 5 mg AA/day for up to 30 
days, the control group was kept on deficient diet for 16 days. Hepatic aniline hydroxylase, 
cytochrome P-450, acid phosphatase, SAP activities were better in the supplemented groups but there 
was no difference between the 3 groups. Subsequently 3 depleted groups were given 5 mg AA/day, 100 
mg IAA/day or 100 mg XAA + 5 mg AA/day for 20 days. All enzyme activities recovered similarly 
(Suzuki, E. 1989). 
Groups of 4 female Swiss-Webster mice were fed 5% IAA in the diet for 2 months followed by 10% IAA 
for 5 months. About 40% of endogenous hepatic AA and 31% of brain AA were replaced by IAA, 
thereby reducing the bioavailability of AA. Plasma levels remained unaffected. The body weight 
gain of IAA animals was reduced. Thus overall competitive replacement of AA occurred to a 
considerable degree (Tsao, C.S. et al 1983). 
Male cynomolgus monkeys were kept for 8 weeks on a depletion diet and the repleated for 4 weeks 
with either 10 mg/kg b.w./day AA or 10 mg AA + 200 mg IAA/kg b.w./day. There was no difference in 
the blood ascorbate levels of the treated groups showing an absence of antagonistic action of IAA 
(TumbuU, J.D. et al 1979). 11 adult women were maintained for 24 days on a AA-free formula diet and 
then given gradually increasing AA supplements with or without 600 mg/day IAA. Some subjects 
became scorbutic and blood ascorbate was reduced markedly during depletion. Addition of 30 mg AA, 
60 mg AA or 90 mg AA/day for 10 days was only effective in restoring blood AA levels, when 90 mg 
were used. Addition of 600 mg IAA caused no adverse and perhaps a slight sparing effect (Säuberlich, 
H.E. 1989). 
Oxalate formation 
Conversion of AA to oxalate is a minor metabolic pathway. Reported values vary greatly but high 
intakes are mostly associated with increased urinary oxalate (51). Rats fed 2% (= 424 mg AA/kg b.w.) 
or 5% (= 1060 mg AA/kg b.w.) ascorbyl palmitate daily in the diet for 9 months were compared to a 
group given 1% IAA. 2 animals given ascorbyl palmitate had oxalate stones in the bladder (Fitzhugh, 
O.G. 1946). Human volunteers given AA or IAA showed little degradation of IAA to oxalate. 90 
mg/day AA increased urinary oxalate as much as 600 mg IAA/day (Sauberlich, H.E. 1989). 
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Effects on metal absorption 
Lp. 1 g/kg b.w. of IAA or L-AA produced the same increase in mouse liver metallothioneines (56' 
Adult male volunteers given for 51 days a diet containing 200 g processed meat (uncured, nitrite cured 
nitrite + 500 μg/g IAA cured sausage) showed no significant effects on the bioavailability an< 
absorption of Fe, Zn, Cu, on serum Zn and serum Cu levels, plasma ferritin, transferrin o 
coeruloplasmin levels (Greger, J.L. 1984). Iron-deficient rats fed for 2 weeks on diets containing uncurec 
meat or meat cured with 550 pg/g IAA, 156 pg/g nitrite or IAA + nitrite, showed no effect on iroi 
absorption or incorporation into tissue (Lee, K. et al 1984; Lee, K. et al 1985; Mahoney, A W. et a 
1985). A similar test using constant Zn and Cu levels in the diets showed no effects on Zn and Ci 
utilisation, although high levels of AA in the diet of guineapigs, chicken and rats apparenti) 
depress Cu utilisation (Greger, J.L. 1985). 
Other biological effects 
2 groups of guineapigs were fed an AA-free diet with either skimmed milk or gluten as protein source 
for 10 days. One group received i.p. 800 mg/kg b.w. Na-IAA for 11 days, the other 5 mg AA/kg b.w. 
orally. No adverse effects or differences in body weight were seen. The adrenals had the highest IAA 
tissue level. Organ distribution of IAA was unaffected by the type of protein fed (Williams, H.S. 
1972). 
A group of 20 or more 2-days old suckling Sprague-Dawley rat pups were given by gavage for 10 or 25 
days either saline, AA at various percentages of total milk solids consumed or IAA at 2% of total milk 
solids consumed. Lung collagen concentrations, lung weight and liver weight were unaffected. Rates of 
lung protein and elastin synthesis were lower by 25-30% in the AA and IAA treated pups. 
Pressure-volume curves were not affected. Lung tissue of AA-treated pups was less mature 
(Critchfield, J.W. 1988). 
4 groups, each of 5 male guineapigs, were fed for 43 days diets containing 0.2% AA, 8.7% AA free acid, 
8.7% mixed K, Na and Ca salts of AA or 8.7% mixed K, Na and Ca salts of IAA. 8.7% free AA acid but 
not the salts decreased bone density and urinary hydroxyproline. 8.7% free IAA did not cause bone 
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Short-term studies 
Mouse: 
5 groups, each of 6 weanling mice, received in their diet either 0, 2% 5% or 10% glucoascorbic acid, 
10% AA or 5% IAA. Glucoascorbic acid caused severe scurvy with weight loss, diarrhoea and 
cutaneous haemorrhages at 5% and 10%, mild scurvy at 2% but normal growth and health were seen 
with 10% AA or 5% SAA (WHO 1974). 
5 groups, each of 10 male and 10 female B6C3F1 mice aged 8 weeks, were given 0.625%, 1.25%, 2.5%, 
5% and 10% Na-IAA in their drinking water for 10 weeks. 20 males and 20 females were the controls 
on distilled water. Males on 5% IAA gained less weight than controls, females on 5% IAA exceeded 
control weights. Histology showed marked atrophy of liver cells and lymphoid follicles of spleen 
(males at 5 and 10%, females at 10%) and hydropic degeneration of renal tubular epithelium at the 
same levels (Inai, K., 1989). 
Rat: 
2 groups, each of 10 male weanling Osbome-Mendel rats, were fed for 36 weeks 0 or 1% L-IAA in their 
diet. There were no significant differences from controls regarding growth, weight gain and mortality. 
Gross pathology and histopathology of lung, heart, liver, spleen, pancreas, stomach, small intestine, 
kidney, adrenal, testis and occasionally examination of colon, lymph node, bone, bone marrow, 
thyroid, parathyroid showed no specific lesions attributable to IAA (Fitzhugh, O.G. 1946). 5 groups, 
each of 10 male and 10 female F344 rats, were given 0.625%, 1.25%, 2.5%, 5% or 10% Na-IAA in their 
drinking water for 13 weeks. All rats on 10% refused to drink and died in 2-5 weeks. 3 males and 1 
female on 5% died in 4 days. All other groups survived. 2.5% depressed body weight by 12% in males 
and 6% in females. No other parameters were reported (Abe, I. et al 1984). 
Long-term studies 
Mouse: 
3 groups, each of 50 male B6C3F1 mice, were given 0,1.25% or 2.5% Na-IAA in their drinking water, 3 
groups, each of 50 female B6C3F1 mice, were fed 0, 2.5% or 5% in their diet for 96 weeks. Final 
sacrifice was at week 110 following 14 weeks recovery. Average body weights were similar to controls 
but final body weights were higher in survivors. Treated animals survived better. Tumour incidence at 
any site and time to tumour did not differ significantly from controls. The minimal effect level in male 
mice was 3.3 g/kg b.w. and in female mice 4 g/kg b.w., reduced relative brain weight occurred at these 
doses. Hepatocellular adenomas and carcinomas were increased in male mice at 4-9 g/kg b.w. but the 
incidence in controls was unusually low and this effect disappeared after adjustment for survival. 
Chronic toxic effects were not reported in detail (Inai, K., 1989). 
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Rat: 
2 groups, each of 10 rats (sex not stated), were fed diets containing 0 or 1% IAA for 2 years. No adversf 
effect on growth, mortality and histopathology (organs and lesions not listed) were observée 
(Lehman, A.J. 1951). 3 groups, each of 10 male weanling Osbome-Mendel rats, were given normal diei 
containing 5% lard with 0, 0.05% or 0.25% dietary IAA-palmitate for 2 years. Growth and mortalit) 
were similar to controls. Occasional haematology during the first year showed no toxic effects 
Histopathology (organs and lesions not specified) showed no gross or microscopic differences frorr 
controls nor any distinct lesions attributable to treatment (Fitzhugh, O.G. 1946). 3 groups, each of 52 
male and 52 female F344/Du Cr rats, were given for 96 weeks in their drinking water 0,1.25% or 2.5% 
Na-IAA. 2.5% depressed body weight gains in both sexes but more in females during the 2nd year. 
Mean lifespan was similar in all groups. No specific tumours and no shortening of time-to-tumour 
attributable to treatment were noted. Chronic toxic effects were not properly investigated but a few 
lesions occurred in high dose rats (Abe, I. et al 1984). 
Dog: 
4 beagles received a total of 1 g IAA daily orally for 240 days. Another group of 4 beagles received 5 g 
IAA for 50 days followed by 7.5 g daily for 190 days. No toxicity was observed. Body weights, growth, 
haematology were normal. No gross or histopathological changes due to treatment were noted 
(Orahovats, P.D. 1957). 
Reproduction studies 
A formal multigeneration-reproduction study has not been carried out with IAA. 
Teratogenicity studies 
Mouse: 
Pregnant CD-I mice were given IAA at 0,10.3,47.6,221.9 or 1030 mg/kg b.w. by gavage from day 6 to 16 
of pregnancy. No adverse effects were noted on maternal or foetal survival and no soft tissue or 
skeletal teratogenic effects were noted (FDRL 1974). 
Rat: 
Pregnant Wistar rats were given IAA at 9.0, 41.8,194.0 or 900 mg/kg b.w. in their diet from day 6 to 16 
of pregnancy. No adverse effects on maternal or foetal survival and no soft tissue or skeletal 
teratogenic effects were noted (FDRL 1974). 
Pregnant Wistar rats were given diets containing 0, 0.05%, 0.5% or 5% IAA from day 7 to 14 of 
pregnancy. No adverse effects were noted on body weight gain, foetal deaths, litter numbers, foetal 
sex ratio, foetal body weight and placental weight. No soft tissue or skeletal teratogenic effects were 
seen. Postaatal development was unaffected (Ema, M. 1985). 
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Chicken: 
IAA had embryotoxic effects closely related to the dose injected into the air sac or yolk of fertilised 
eggs. Embryonic mortality was increased and more abnormal chicks hatched but histopathology was 
inconclusive. The LC50 at 96 hours via air cell was 84 mg/kg (Naber, E.C. 1975; Hwang, U.K. et al 
1974, Newell, G.W. et al 1974). 
Mutagenicity studies 
1. Bacterial tests: 
A salmonella reverse mutation test with TA 100 +/- S9 using IAA free acid was weakly positive and 
dose dependent up to 20 mg/plate. Na-IAA and AA were negative up to 5 mg/plate (Ishidate, M., 
1984). 
A salmonella reverse mutation test (strains not mentioned) was negative up to 0.5% (w/v) IAA (Litton 
Bionetics 1976). 
A salmonella reverse mutation test in TA 1530,1535,1536,1537,1538 +/S9 was negative (Newell, 
G.W. 1974). 
A salmonella reverse mutation test in TA 98 was negative for Na-IAA (Kawachi, T. et al 1980). 
A salmonella reverse mutation test in TA 98 and TA 100 +/- S9 was negative for Na-IAA (Peters, J.H. 
et al. 1983). 
2. Yeasf rests: 
IAA was mutationally inactive against Sacch. cerev. at concentrations of 2% and 4% (Litton Bionetics 
1976). 
Concentrations of 5% Na-IAA did not increase mitotic recombination frequency in Sacch. cerev. D3 
(Newell, G.W. et al 1974). 
3. Host-mediated assays: 
Na-IAA was not mutagenic in a host-mediated assay using Salm. typhim.TA 1530 or Sacch. cerev. D3 
(Newell, G.W. et al 1974). 
4. In vitro mammalian cell assays: 
Na-IAA and IAA were inactive in Chinese hamster fibroblast (CHL) cells for chromosomal 
aberrations up to 0.25 mg/ml and 48 hour incubation (Ishidate, M. et al 1984). Na-IAA caused no 
chromosomal aberrations in CHL fibroblasts with S9 (Matsuoka, A. et al 1979). No chromosomal 
aberrations or SCEs were induced in human fibroblasts (HE2144) at doses of 0.02 mg Na-IAA/ml for 
40-48 hours (Kawachi, T. et al 1980; Sasaki, S. et al 1980). 
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5. Micronucleus test: 
A test in rat bone marrow was reported positive for Na-IAA but insufficient details are reported to 
assess validity (Kawachi, T. et al 1980). 
A test in mice using i.p. IAA up to a single dose of 1500 mg/kg b.w. or 4 daily doses of 750 mg/kg b.w. 
was negative (Hayashi, M. et al 1988). 
6. Dominant lethal test: 
Na-IAA was tested in rats at dose levels of 0, 0.2, 1.0 and 5.0 g/kg b.w given either once or on ï 
successive days. The positive control was 0.2 mg TEM/kg b.w. given i.p., breeding being carried oui 
over 8 weeks. No treatment-related changes in early and late foetal deaths, corpora lutea and 
preimplantation losses were noted. Occasional significant differences were neither time- noi 
dose-dependent (Newell, G.W. et al 1988). 
7. Heritable translocation test: 
Adult male mice were treated for 7 weeks with dietary levels of 1% or 5% Na-IAA, positive control 
being 4 weeks' treatment with TEM in the drinking water. 100 Fj males from each group were mated 
with 3 females each and the nonbreeders, presumptive steriles and partially steriles identified. 
Rebreeding left 3 controls, 20 TEM and 3 IAA treated males. Cytogenetic evaluation of meiotic 
chromosomes showed heritable reciprocal translocations only in the TEM-treated males. There was no 
effect on male fertility (Jorgenson, T.A. et al. 1978; Newell, G.W. et al 1988). 
Studies on mutagenicity modulation 
The modulating effect of human urine concentrates on the mutagenic or promutagenic activities of 
2-acetylaminofluorene, 2-anthramine and 2,3,6-trinitrotoluene on Salm. typhim. TA 98 and TA 100 
were not changed consistently, whether 30, 60 or 90 mg AA or 600 mg IAA/day were ingested 
additionally (Peters, J.H. et al. 1983). 
Studies on tumour promotion 
Using various models of initiator followed by IAA or Na-IAA no promoting effect of AA or IAA could 
be demonstrated. An enhanced carcinogenic response could be observed only when Na-AA and Na-IAA 
were given at 5% in the diet. Promotion effects were limited to forestomach, colon and urinary 
bladder. This suggests that the Sodium ion rather than the AA or IAA are responsible (Fukushima, 
S., et al. 1986; Fukushima, S., et al. 1986; Fukushima, S., et al. 1986; Fukushima, S., et al. 1987; 
Shibata, M.A. et al. 1989). Electronmicroscopy of rat bladder epithelium showed hyperplasia only in 
animals given 5% Na-AA or Na-IAA but not with 5% AA (Fukushima, S. et al. 1986). Similarly only 
Na-AA but not AA increased DNA synthesis in the bladder epithelium (Shibata, MA. et al. 1989). 
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Comments 
Antiscorbutic activity 
Although the apparent antiscorbutic activity of single doses of IAA is about 5% of that of AA, large 
doses over prolonged periods will relieve the symptoms of scurvy. IAA competitively inhibits the 
stereospecific carriers of the transport mechanism of AA in the gut mucosa and membranes of different 
tissues but is a poorer substrate with about l/5th affinity for the carrier. Hence higher IAA 
concentrations are needed to achieve antiscorbutic effects. AA in the tissue compartment with low 
affinity and high turnover (adrenals, lung, kidneys, testis, eye) is easily replaced by IAA but not in 
the tissue compartment with high affinity and low turnover (brain). IAA reduces the AA body pool, 
increases AA catabolism and reduces AA half-life by more rapid elimination of AA. IAA in adequate 
amounts has AA potency as shown in enzyme studies but no conclusions are possible regarding any 
effect on the bioavailability of AA, the evidence being contradictory. 
Absorption 
The intestinal absorption of IAA proceeds by an active carrier-mediated mechanism in guineapigs and 
man but by passive diffusion in rats, mice, hamsters and rabbits. Comparison of the plasma levels of 
IAA following prolonged oral administration to mice in one study (Tsao, C.S. et al 1983) with another 
study in human volunteers (Sauberlich, H.E. et al 1989) demonstrates similar plasma levels despite 
an order of magnitude lower intake in the human volunteers. This difference could be due to the active 
carrier-mediated mechanism in man leading to greater gut absorption and /or tubular reabsorption. No 
study is available which enables a direct comparison of the rates of absorption by the two 
mechanisms in rodents and man. If the present uses of IAA were to be considerably extended adequate 
studies on comparative absorption rates in rats and man as well as the establishment of oral dose 
levels to achieve appropriate plasma levels in rats and mice would be essential. 
There is no evidence for IAA interference with Fe, Zn or Cu absorption from cured meat. 
Metabolism 
Although no specific detailed studies have been carried out on the metabolism of IAA, urinary 
dehydro-IAA was detected in one rat study, indicating that IAA can be a substrate for ascorbate 
oxidase. In another rat study, using both 14-C-labelled IAA and AA, the metabolite 
ascorbate-2-sulphate but no isoascorbate-2-sulphate was detected in the urine. In man, oxalate 
excretion is greater with AA than with IAA (Sauberlich, H.E. et al 1989). Although this 
demonstrates certain differences in the metabolism of IAA and AA in rat and man, it is likely that 
there are at least qualitative though not quantitative similarities. In interpreting the relevance of 
toxicity studies in rats to man, it should be noted that the diketo-gluconate pathway is absent in man. 
Further studies to more fully elucidate the metabolism of IAA would be desirable, bearing in mind, 
however, that even the metabolism of AA has not been completely established. 
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Excretion 
IAA is largely excreted in the urine, renal tubular reabsorption being less efficient but using the samf 
transport mechanism as AA. IAA could therefore compete with and reduce AA reabsorption 
Experiments on human volunteers show no depletion of AA due to IAA intake but the animal evidence 
is contradictory. 
Toxicity/Carcinogenicity 
The more recent short-term study in mice did not show any specific toxic effects up to 2.5% IAA in 
their drinking water, higher doses causing reduced weight gain as well as liver, kidney and spleen 
toxicity. The available recent carcinogenicity study in mice (Inai, K. et al 1989) resulted in a minimal 
effect level of IAA for male mice of 3.3 g/kg b.w. and female mice of 4 g/kg b.w., when administered in 
their drinking water (reduced relative brain weights occurred at these doses). Hepatocellular 
adenomas and carcinomas were increased in male mice at 4.9g/kg b.w./day but the incidence in 
controls was unusually low and the effect was no longer apparent after adjustment for survival. 
Chronic toxic effects were not reported in detail, although it was stated that no significant 
histopathological differences were noted between treated and control groups. 
An early 36-weeks feeding study (Fitzhugh, O.G. et al 1946) in rats used only male animals and a 
single dose level. The reported findings in gross pathology and histopathology showed no evidence of 
any specific toxic effects attributable to IAA. This study was however inadequate by modern 
requirements. Another more recent short-term study (Abe, I. et al 1984) pointed to a NEL of about 
1.25% in the drinking water, higher doses causing loss of weight. As no other parameters were 
reported, this study is also regarded as inadequate. 
The recent life-span carcinogenicity study in rats (Abe, I. et al 1984), using administration in the 
drinking water, did not show any carcinogenic effects, the NEL being 1.25%, higher doses causing 
reduced bodyweight gain. Chronic toxic effects were not properly investigated - no incidences were 
reported although a few lesions occurring in high dose rats were described. The inadequacies of this 
recent study regarding chronic toxic effects is partially offset by the life-span study in mice mentioned 
above. The latter study stated there was no evidence for the occurrence of specific toxic lesions 
attributable to dietary administration of IAA, although again no incidences of lesions were given. 
Reproductive toxicity 
A formal multigeneration-reproduction study has not been carried out with IAA. However, the 
dominant lethal study in rats and the heritable translocation study over several generations in mice 
show no evidence of any significant interference by IAA at least with male reproductive function, as 
only the males were treated. No conclusions on female reproductive function can be derived from these 
studies. 2500 mg/kg b.w. in rats and 1030 mg/kg b.w. in mice caused no teratogenic effects. 
Genotoxicity 
IAA was adequately and extensively tested for somatic and germ cell mutagenicity in several in vitro 
and in vivo systems and was shown to have no genotoxic potential. IAA has also no tumour-promoting 
activity in several model systems testing for promoter activity. 
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EXPRESSED ON 2 JUNE 1995 
1. Terms of reference 
To advise on the acceptability with respect to safety in use of acetylated oxidised starch. 
2. Background 
A submission was received on 14.06.1991 requesting permission to use acetylated oxidised starch (AOS) 
as a food additive. No toxicity data were submitted at that time in support of this request. A W/G of 
the SCF considered the application at their meeting of 7-8.11.1991. It noted that acetylated starch 
and oxidised starch (starches in group B, see second Series of Reports, 1976) were already considered 
acceptable in their own right. However, to have more complete reassurance of the safety of a 
modified starch subjected to a combined treatment of acetylation and oxidation, it required a 90-day 
feeding study and a more precise specification setting out the degree of modification as well as 
proposing maximum limits for residues of reactants and byproducts such as sodium chloride, sodium 
chlorate, sodium sulphate and sulphur dioxide. 
At the 81st meeting of the SCF of 9-10.12.1991 the Committee considered AOS temporarily acceptable 
pending receipt of the results of a 90-day feeding study and an adequate specification within 2 years. 
A full report on a 90-day feeding study in rats has now been submitted early in 1994 together with a 
specification for those products which had received the highest treatment and which were the 
subject of the 90-day study. 
3. Specification 
Degree of substitution for acetyl: 
Degree of substitution for carboxyl: 
Residual reactants 
0.04 - 0.07 to 0.10 mol/mol or 
1.1 -1.8 to 2.5% w/w 
0.022 - 0.037 to 0.047 mol/mol or 
0.6 -1.2 to 1.3% w/w 
SO2 maximum 5 ppm 
NaCl less than 0.1% (conductivity less than 
300 uS/cm equivalent to less than 0.03% NaCl) 
all other residues and byproducts 10-100 ppm 
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4. Subacute (dose range finding) study 
4 groups, each of 5 male Wistar rats, 4-5 weeks old and housed 5 per cage, were fed for 2 weeks in their 
diet either 0%, 10%, 30% or 50% extruded AOS. 1 additional group was fed 30% non-extruded AOS. 
Only body weight gain, food intake, food efficiency and the weight of filled and empty caeca were 
deteimined. Weight gain, food intake and food efficiency were comparable among all groups. The 
absolute and relative filled and empty caecal weight was increased in the groups fed 30% and 50% 
AOS and in the group fed 30% nonextruded AOS. Animals given 50% AOS showed diarrhoea and 
considerable caecal enlargement. On the basis of these findings the dose range for the 90-day study 
was set at 0%, 5%, 10% and 30% in the diet. 
5. Subchronic study 
4 groups, each of 10 male and 10 female Wistar rats, aged 4-5 weeks, were fed for 13 weeks in their 
diet 0%, 5%, 10% or 30% extruded AOS. Body weight gain and food consumption were measured 
weekly, urinalysis was carried out in week 12, ophthalmoscopy was performed on all groups at the 
start and in controls and the top dose group in week 12. Full haematology and clinical chemistry 
including ALP, ASAT, ALAT, GGT estimations were performed once in week 14. Relative organ weight 
were determined in all dose groups for testes, pituitary, thyroid, adrenals, kidneys, thymus, brain, 
spleen, heart, liver and empty and full caecum. Histopathology of 33 organs was performed on all 
animals of the control and top dose group. In all other test groups only kidney, liver, lung and urinary 
bladder were examined. 
No abnormal clinical signs or behavioural abnormalities were observed. No mortalities occurred. 
Body weight gain, food intake and food efficiency were comparable among test and control groups. 
There were no treatment-related changes in the haematological, blood clotting and clinical chemistry 
parameters and all values were comparable between control and test groups. Urinalysis showed no 
treatment-related changes. All organ weights were comparable between test and control groups, but 
the absolute and relative weights of filled and empty caecum were increased in the 30% test group. 
One male rat in the 30% group had a dilated caecum. 
Some males and females in all groups except the females given 5% AOS showed a slight increase in 
the incidence of hyperplasia of the transitional renal pelvic epithelium particularly in top dose 
males and females compared to controls. However none of the increases was statistically significant. 4 
out of 10 males in the 30% test group showed focal hyperplasia of the bladder epithelium. This was 
not seen in any other test group nor in the control group. Mineralisation in the pelvic renal epithelium 
as well as some renal cortical and cortico-medullary rnineralisation was seen in all groups and 
especially in the top dose female group. There were a few aggregates of RES cells in the liver of males 
of the 5% dose group and less so in the 10% and 30% dose groups as well as in all female test and 
control groups. A dose-response relationship was not discernible. This finding is common for the strain 
and age of the rats used. 
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6. Comments 
The increased weight of filled and empty caecum in rats of the top dose was not associated with any 
histopathological changes in the caecal wall or elsewhere in the GI-tract. It is a well-known response 
to high dietary levels of poorly digested carbohydrates in rats, the probable mechanism being the 
increased osmotic load from the SCFA produced by microbial degradation and the associated water 
retention. 
The changes in the urothelial epithelium of the renal pelvis are similar to those found in feeding 
tests with other chemically modified starches in rats and in mice and are associated with 
mineralisation. The hyperplasia of the urinary bladder epithelium, seen only in males of the top 
dose group is probably treatment-related and a consequence of bladder irritation by calculi. There 
were no other significant pathological findings in any of the test groups. 
7. Conclusions 
The NOEL in this study was 10% of AOS in the diet. In the absence of any specific adverse findings 
associated with the feeding of AOS the Committee is of the opinion that AOS can be included among 
the other modified starches in group Β which is considered acceptable (13th Series of reports of the 
Scientific Committee for Food, 1982) and for which the establishment of individual ADIs was judged 
to be unnecessary provided the technological usage remained at present-day levels, an aspect to be 
kept under review by the Commission. The specification supplied is adequate. 
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1. Terms of reference 
The Committee is asked to evaluate the risk to human health arising from dietary exposure to 
cadmium with particular reference to exposure from animal meat and organs. 
2. Background 
Concern over reports of high levels of cadmium in the organs and meat of horses imported into the 
European Union prompted the Commission to ask the Committee to cany out a general review of risk 
to public health arising from dietary exposure to this element. 
The Committee endorsed the JECFA PTWI of 7 pg/kg b.w in its opinion expressed on the 7™ December 





The Committee noted that its ability to assess the dietary exposure to cadmium in EU was greatly 
limited by the availability of reliable data on the consumption of relevant foodstuffs by individuals. 
This is particularly important in the case of cadmium since, with the exception of cigarette smoke and 
work place air, the contribution of non-dietary medium-contaminated sources to the exposure of the 
general population is negligible in comparison to the diet. 
The average dietary exposure of European populations to cadmium, as indicated by monitoring 
programmes or from studies in smaller population groups, ranges from 100 to 400 pg/person/week (23 to 
95% of the PTWI for a 60 kg person). Estimates vary appreciably even in the same country. The 
overall conclusions may therefore need to be reviewed in the light of better information. 
In relation to the specific question regarding exposure from animal muscle and organs, the Committee 
noted that the cadmium contents of muscle, liver and kidney were largely independent of the species 
with the notable exception of the horse for which cadmium levels are considerably higher. The 
cadmium content of liver and kidney is known to increase with age and the Committee concluded that 
these higher levels arise from the tendency to slaughter horses at a considerably greater age than 
most other animals intended for meat production. Similar considerations may therefore be expected to 
apply to other species slaughtered at relatively greater age but no data were available to the 
Committee to support this assertion. 
The following table summarises the reported consumption data and cadmium levels in animal muscle 
and organs. The ranges of maximum limits (MLs) in force in the Member States are included for 
comparison. 
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1 values for consumption and cadmium content excluding horse meat and organs 
2 no separate ML for horse kidney in the countries with this limit 
3 assumed to be 2.5 times average consumption 
4 derived from data on horse offal and assumes consumption of liver and kidney in the ratio 2 to 1 
On the basis of a PTWI of 7 pg/kg b.w. and mean body weight of 60 kg: 
- for average and high consumers of meat in general and non-horse organs, the cadmium intake 
ranges from 2 to 13% of the PTWI for products having average cadmium contents and from 8 to 83% 
for those having high cadmium contents. 
- for average and high consumers of horse liver and horse kidney, the cadmium intake ranges from 
34 to 208% of the PTWI for products having average cadmium contents and from 67 to 645% for 
those having high cadmium contents. 
It is stressed that the above estimates are based on the reported current dietary consumption patterns 
and increase in the proportion of horse meat and offal consumed would lead to greater cadmium 
exposure. 
The Committee concludes that for a significant part of the population, exposure to cadmium from 
dietary sources alone is at a level close to the PTWI. It therefore recommends greater effort to reduce 
dietary exposure and the continuation of regular and comprehensive monitoring of this element in the 
diet of the population of the European Union. 
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In the particular case of horse meat and organs, it appears that at the current levels of consumption by 
individuals, products sold in conformity with typical maximum residue limits in force in the Member 
States would not pose a risk. However, the great majority of horse liver and kidneys have cadmium 
contents which greatly exceed these limits and their consumption is likely to lead to unacceptable 
levels of cadmium exposure. 
Carcinogenicity 
During the course of this evaluation, the Committee noted that, since its previous opinion of December 
1989, the results of a number of carcinogenicity studies had become available and that IARC had 
recently classified cadmium and its compounds as human carcinogens in Group 1 (IARC 1993). The 
Committee therefore reviewed the aspect of carcinogenicity in order to complete its re-evaluation of 
the toxicology of cadmium from all dietary sources as a matter of urgency. 
Cadmium is a cumulative element with a biological half-life of 10-20 years in humans. Kidney 
disfunction has so far been considered to be the critical effect of long term exposure to cadmium and 
quantitative risk assessments have been performed accordingly. 
Recently, IARC classified cadmium and cadmium compounds in Group 1 (Human carcinogens), based on 
evidence from human studies, mainly those on lung cancer associated with cadmium inhalation in the 
work place, and from animal studies (mainly two inhalation studies in rats producing malignant 
tumours and one oral study in male rats producing leukemias, interstitial cell tumours of the testis and 
proliferative lesions of the prostate). The IARC classification is qualitative only. Supportive 
evidence was also provided by the genotoxic effects induced in several eukaryotic cells, in vitro and in 
vivo, including human cells. 
Concerning the interpretation of animal and human data and in particular the question whether 
cadmium should be considered only or primarily carcinogenic by inhalation, a number of important 
issues should be taken into account: 
- the uncertainties on the mechanisms of cadmium carcinogenicity; 
- the limitations of the currently available animal studies involving oral exposure; 
- the need for clarification of the role of metalothionein, particularly in relation to carcinogenicity 
and genotoxicity; 
- the roles of various cadmium compounds and their bioavailability; 
- interaction with other metals (Zn, Fe, Cu). 
The available data do not allow adequate quantitative assessment of carcinogenic risk However, the 
carcinogenic risk associated with dietary exposure appears to be much lower than that from direct 
inhalation. 
Concerning the genotoxicity data, despite some conflicting information, taken overall the data suggest 
that the genotoxic activity is a common trait of cadmium compounds. However, different types of 
evidence suggest indirect modes of action (e.g. oxidative damage by reactive oxygen species, 
interaction with critical thiol groups of proteins, inhibition of DNA repair enzymes) especially at 
the chromosome and genome level. 
Reports of the Scientific Committee for Food (Thirty-sixth series) 69 2 JUNE 1995 CADMIUM 
The Committee concluded that, at present it cannot exclude a carcinogenic risk from dietary exposure 
to cadmium, and is therefore unable to establish a safe level for cadmium in food. Epidemiological 
data collected on environmentally exposed populations during the last two decades have provided a 
sound basis to conclude that alterations of kidney function should be regarded as the critical effect of 
cadmium. For this reason, and in view of the narrow safety margin between the cadmium body burden 
of the general population in the Europe Union and the critical level for renal disfunction, there is a 
need to keep dietary exposure to cadmium as low as possible. 
The present PTWI of 7 pg/kg b.w. is still considered to be valid for renal dysfunction but should be re-
evaluated as soon as further information concerning carcinogenicity or mutagenicity becomes 
available. 
Reference 
International Agency for Research on Cancer (IARC) Monograph on the evaluation of carcinogenic 
risks to humans. Vol 58. Beryllium, cadmium, mercury and exposures in the glass manufacturing 
industry. Lyon 1993. 
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OPINION EXPRESSED ON 2 JUNE 1995 
1. Introduction 
In the past, the SCF has evaluated a number of esters including esters of adipic, azelaic, citric, 
phosphoric, phosphorous, phthalic, sebacic, sulphosuccinic, thiodipropionic and trimellitic acids. 
Several of these have already been classified in lists 1, 4A or 6A and they do not appear in this 
report. For esters not classified in the above lists, the SCF has made recommendations about the 
studies which need to be carried out in order that a full evaluation can be made. All these 
recommendations, previously published in separate documents are brought together in this report. The 
corresponding Community Directive reference number precedes the entry for each substance. The 
definitions of the lists are given in the Appendix. 
N.B. For a number of the substances, the additional requested data have been made available but have not 
been evaluated at the time of adoption of the present report. 
i) Hydrolysis studies 
These have been requested for those monoesters which may hydrolyse to substances which are 
already in lists 0,1, 2 and 3 (see Practical Guide N.l, 2 April 1993). 
ii) 28-day oral studies 
These have been requested in some instances because some subchronic data were already available but 
were not adequate to establish a TDI. Where 28-day studies have been requested, the wg expects that 
group sizes, histopathology, haematology, clinical chemistry and urinalysis will conform to the 
present day standards of 90-day studies. However, note that 28-day or 90-day studies need only be 
provided if migration exceeds 0.05 mg/kg of food (see Practical Guide N.l, 2 April 1993). 
iii) Peroxisome proliferation studies 
These have been requested, in principle, for all alkyl esters because there is evidence to indicate that 
both branched and unbranched esters of differing chain lengths may cause peroxisomal proliferation. 
These data have not been requested for cycloaliphatic or aromatic esters because there is no evidence 
to suggest that they cause peroxisomal proliferation. 
However, for linear chain esters, a study of peroxisome proliferation is not required provided the 
restriction resulting from other toxic effects is < 0.05 mg/kg b.w. If there are no other toxic effects 
which invoke a restriction of < 0.05 mg/kg b.w., then in the absence of a peroxisome proliferation 
study, the SCF will set a restriction of 0.05 mg/kg b.w.. This approach is based on the assumption that 
di-2-ethylhexyl phthalate (DEHP, which has a restriction of 0.05 mg/kg b.w. based on peroxisome 
proliferation) is considered to be the most potent peroxisome proliferator among esters used as 
monomers and additives in food contact materials. 
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For esters in general, a study of peroxisome proliferation will not be required if structure-activity 
arguments, based on adequate scientific evidence, can be provided which show that peroxisome 
proliferation would not be expected to occur. This approach is based on the growing knowledge about 
structure-activity relationships for peroxisome proliferation. 
Where peroxisome proliferation studies are conducted, they should be carried out in the rat and 
dosing should be a minimum of 14 days in duration. At least the following two markers should be 
measured: palmitoyl CoA oxidation and lauric acid 12-hydroxylase. The following methods to assess 
these activities are recommended: 
Palmitoyl-CoA oxidation: a spectrophotometric assay based on the methods of either Lazarow or 
Bronfman. 
Lazarow PB and DeDuve C. Proceedings of the National Academy of Sciences 73 (1976), 2043-2046. 
Lazarow PB. Methods in Enzymology 72 (1981), 315-319. 
Bronfman M, Inestrosa NC and Leighton F. Biochemical and Biophysical Research 
Communications 88 (1979), 1030-1036. 
Lauric acid 12-hydroxylase: a radiometric assay using radiolabelled substrate and HPLC to separate 
individual hydroxy metabolites from unmetabolised substrate. 
Parker GL and Orton TC In: Biochemistry Biophysics and Regulation of Cytochrome P-450. Eds: 
Gustafsson J-Α, Duke JC, Mode A and Rafter J. pp 373-377. Elsevier/North Holland, Amsterdam 
(1980). 
Sharma R, Lake BG, Foster J and Gibson GG. Biochemical Pharmacology 37 (1988), 1193-1201. 
However, note that these data need only be provided if migration exceeds 0.05 mg/kg of food (see 
Practical Guide N.l, 2 April 1993). 
iv) Neurotoxicity studies 
These have been requested for phosphoric acid and phosphorous acid esters because there is evidence 
that a number of substances in the group have neurotoxic properties. Measures of anticholinesterase 
activity plus either a standard test in chickens for delayed neuropathy or measurement of inhibition 
of neuropathy target esterase (ΝΤΕ) would be appropriate. However, note that these data need only 
be provided if migration exceeds 0.05 mg/kg of food. 
v) Reproduction and teratogenicity studies 
These have been requested because there is evidence that a number of substances in the group have 
adverse effects on reproduction and/or are teratogenic. However, note that, with the exception of 
substances having a t-TDI, these data need only be provided if migration exceeds 5 mg/kg of food (see 
Practical Guide N.l, 2 April 1993). 
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vi) Mutagenicity studies 
These have been requested according to the Practical Guide N.l (2 April 1993), which requires 3 
particular types of test, irrespective of the level of migration. 
N.B. DEHA and DEHP have not been included in this re-evaluation because the SCF will publish separate 
opinions on them. However, the group restriction of 0.05 mg/kg b.w. for certain of the esters listed 
below (which are suspect for peroxisome proliferation) is based on the most recent evaluation of the 
peroxisome proliferation activity of DEHP, for which a TDI of 0.05 mg/kg b.w. has been agreed. 
Classification of individual esters 
N.B. With the exception of substances having a t-TDI, for all remaining esters mentioned below it is 
necessary to provide migration data according to the Practical Guide N.l, 2 April 1993. In the case of 
substances having a t-TDI, the studies specified are required in order to establish a full TDI. 
1. The following substances are classified in List 6B with a group restriction of 0.05 mg/kg b.w and 
require: 
a ) toxicological data depending on level of migration (see SCF guidelines) 
and 
b) if the migration exceeds 0.05 mg/kg also the additional study specified below: 
- peroxisome proliferation study 
c) any other data specified beside the substance. 
Monomers 
12190 Adipic Acid, Di-n-Decyl Ester 
12220 Adipic Acid, Diisodecyl Ester 
Needed: Specifications on identity 
12235 Adipic Acid, Dimethyl Ester 
12250 Adipic Acid, Di-n-Octyl Ester 
12910 Azelaic Acid, Dimethyl Ester 
24340 Sebacic Acid, Di-n-Decyl Ester 
24370 Sebacic Acid, Dimethyl Ester 































Adipic Acid, Bis(6-Methylheptyl) Ester 
Adipic Acid, n-Decyl n-Octyl Ester 
Adipic Acid, Dibutyl Ester 
Adipic Acid, Di-n-Decyl Ester 
Adipic Acid, Diisobutyl Ester 
Available: Inadequate 2 year oral rat study 
Adipic Acid, Diisodecyl Ester 
Needed: Specifications on identity 
Adipic Acid, Diisooctyl Ester 
Needed: Specifications on identity 
Adipic Acid, Dimethyl Ester 
Adipic Acid, Di-n-Nonyl Ester 
Adipic Acid, Di-n-Octadecyl Ester 
Adipic Acid, Di-n-Octyl Ester 
Azelaic Acid, Bis(2-Ethylhexyl) Ester 
Available: Inadequate 90-day study 
Azelaic Acid, Bis(6-Methylheptyl) Ester 
Azelaic Acid, Diisooctyl Ester 
Needed: Specifications on identity 
Azelaic Acid, Di-n-Octyl Ester 
Citric Acid, Dioctadecyl Ester 
Needed: Specifications on identity 
Citric Acid, Tributyl Ester 
Citric Acid, Tri-n-Octadecyl Ester 
Citric Acid, Tris(2-Ethylhexyl) Ester 
Phthalic Acid, Dialkyl (C7-C11) Esters 
Needed: Specifications on identity 
Phthalic Acid, Diisobutyl Ester 
Phthalic Acid, Di-n-Decyl Ester 
Phthalic Acid, Di-n-Nonyl Ester 
Phthalic Acid, Di-n-Octadecyl Ester 
Phthalic Acid, Mixed Esters with Butyl Glycolate and Butanol 
Available: 30 day and 1 year oral rat studies and mutagenicity studies which are 
all inadequate. 
Phthalic Acid, Mixed Esters with Ethyl Glycolate and Ethanol 
Available: 4 month and 2 year rat and 1 year dog studies which are all inadequate. 
o-Phthalic Acid, n-Pentyl Benzyl Ester 
Sebacic Acid, Bis(6-Methylheptyl) Ester 
Sebacic Acid, Dimethyl Ester 
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85520 Sebacic Acid, Di-n-Octyl Ester 
Available: data inadequate (extract from Lefaux book). 
91560 Sulphosuccinic Acid, Bis(l,3-Dimethylbutyl) Ester, Sodium Salt 
91570 Sulphosuccinic Acid, Bis(2-Ethylhexyl) Ester 
91630 Sulphosuccinic Acid, Dihexyl Ester, Sodium Salt 
91650 Sulphosuccinic Acid, Diisobutyl Ester, Sodium Salt 
91665 Sulphosuccinic Acid, Diisodecyl Ester, Sodium Salt 
91672 Sulphosuccinic Acid, Diisotridecyl Ester, Sodium Salt 
91680 Sulphosuccinic Acid, Dioctyl Ester, Sodium Salt 
91720 Sulphosuccinic Acid, Dipentyl Ester, Sodium Salt 
91760 Sulphosuccinic Acid, Ditridecyl Ester, Sodium Salt 
91800 Sulphosuccinic Acid, Isodecyl Ester, Disodium Salt 
93000 Thiodipropionic Acid, Bis(2-Ethylhexyl) Ester 
93040 Thiodipropionic Acid, Dibehenyl Ester 
93120 Thiodipropionic Acid, Didodecyl Ester 
93200 Thiodipropionic Acid, Dihexadecyl Ester 
93280 Thiodipropionic Acid, Dioctadecyl Ester 
93360 Thiodipropionic Acid, Ditetradecyl Ester 
95440 Tris(2-Ethylhexyl) Acetylcitrate 
2. The following substances are classified in List 6B with a group restriction of 0.05 mg/kg b.w. and 
require: 
a ) toxicological data depending on level of migration (see SCF guidelines) 
and 
b) if the migration exceeds 0.05 mg/kg the additional studies specified below: 
- peroxisome proliferation study 
- neurotoxicity studies 
72720 Phosphoric Acid, Di-n-Hexadecyl Esters 
72760 Phosphoric Acid, Di-n-Nonyl Ester 
73840 Phosphoric Acid, Triisobutyl Ester 
74080 Phosphorous Acid, Triisodecyl Ester 
3. The following substances (which are not peroxisome proliferators) are classified in List 6B with a 
group restriction of 0.05 mg/kg b.w. because they are suspect for neurotoxicity and require: 
a ) toxicological data depending on level of migration (see SCF guidelines) 
and 
b) if the migration exceeds 0.05 mg/kg the additional studies specified below: 
- neurotoxicity studies 
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72700 Phosphoric Acid, Cresyl Diphenyl Ester 
72840 Phosphoric Acid, Diphenyl-p-Tolyl Ester 
73920 Phosphoric Acid, Triphenyl Ester 
74020 Phosphorous Acid, 2-tert-Butyl-alpha-(3-tert-Butyl-4-
Hydroxyphenyl) p-Cumenyl Bis(4-Nonylphenyl) Ester 
74040 Phosphorous Acid, Diphenyl Ester 
74160 Phosphorous Acid, Tris-2-(Cyclohexylphenyl) Ester 
74320 Phosphorous Acid, Tris[(3-Ethyl-3-Oxetanyl)-Methyl] Ester 
4. The following substances are classified in List 6B with a group restriction of 0.05 mg/kg b.w. and 
require: 
a ) toxicological data depending on level of migration (see SCF guidelines) 
and 
b) the additional study specified below, if any: 
32160 Adipic Acid, Dialkyl Esters (C7-C9) 
Available: 90-day oral rat study. 
Needed: Specifications in the first instance and if migration exceeds 0.05 
mg/kg peroxisome proliferation study of the specified substance too. 
32640 Adipic Acid, Diisononyl Ester 
Available: 90-day oral rat and dog studies and two mutagenicity studies. 
Needed: Specifications and test for chromosome aberrations in mammalian 
cells in vitro in the first instance and, if migration exceeds 0.05 
mg/kg, peroxisome proliferation study of the specified substance too. 
36480 Azelaic Acid, Di-n-Hexyl Ester 
Available: 90-day and 2 year oral rat and 1 year oral dog studies. 
Needed: If migration exceeds 0.05 mg/kg, peroxisome proliferation study too. 
73600 Phosphoric Acid, Tributoxyethyl Ester 
Available: Ames test, 14 day and 18 week oral rat studies. 
Needed: Full report of 18 week oral rat study by Monsanto (1987). 
73680 Phosphoric Acid, Tributyl Ester 
Available: Ames tests and several subchronic oral rat studies. 
Needed: If migration exceeds 0.05 mg/kg, peroxisome proliferation and 
neurotoxicity studies too. 
74000 Phosphoric Acid, Tris(2-Ethylhexyl) Ester 
Available: Ames test, 90-day and 2 year oral mouse and rat studies. 
Needed: If migration exceeds 0.05 mg/kg, peroxisome proliferation and neuro-
toxicity studies too. 
75200 Phthalic Acid, Di-n-Heptyl Ester 
Available: Ames test. 
Needed: If migration exceeds 0.05 mg/kg, peroxisome proliferation study too. 
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75600 Phthalic Acid, Dimethyl Ester 
Available: Limited oral rat chronic toxicity/carcinogenicity study, oral 
teratogenicity studies in rats and mice, Ames test. 
75840 Phthalic Acid, Di-n-Octyl Ester 
Available: Ames test, peroxisome proliferation study, oral mouse reproduction 
study, inadequate oral rat 90-day study, inadequate oral rat chronic 
toxicity/carcinogenicity study. 
75920 Phthalic Acid, Di-n-Tridecyl Ester 
Available: Ames test. 
Needed: If migration exceeds 0.05 mg/kg, peroxisome proliferation study too. 
85120 Sebacic Acid, Bis(2-Ethylhexyl) Ester 
Available: Ames test and 3 week oral rat study. 
Needed: If migration exceeds 0.05 mg/kg, peroxisome proliferation study too. 
85360 Sebacic Acid, Dibutyl Ester 
Available: 2-year oral rat study and reproduction study in rats both inadequate, 
3 mutagenicity tests (reports not available). 
Needed: Mutagenicity reports in first instance and, if migration exceeds 0.05 
mg/kg, peroxisome proliferation study too. 
94800 Trimellitic Acid, Tris(2-Ethylhexyl) Ester 
Available: Ames test and indication of peroxisome proliferation. 
Needed: If migration exceeds 0.05 mg/kg, peroxisome proliferation study too. 
[Waiting list as it is a new substance.] 
5. The following substances are classified in List 2 but their requirements have been modified as 
follows: 
74560 Phthalic Acid, Benzyl Butyl Ester 
L2 t-TDI: 0.1 mg/kg b.w. 
Available: 6-month oral rat, carcinogenicity and peroxisome proliferation 
studies in vitro (RIVM 1987, September). 
Needed: In vivo peroxisome proliferation study, reproduction and 
teratogenicity studies. 
74880 Phthalic Acid, Dibutyl Ester 
L2 t-TDI: 0.05 mg/kg b.w. 
Available: Limited 90-day and 1-year oral rat studies, oral reproduction and 
teratogenicity studies, limited mutagenicity studies (RIVM Report, 
May 1988). 
Needed: Tests for gene mutation and chromosome aberrations in mammalian 
cells in vitro, and, if migration exceeds 0.05 mg/kg 28-day oral study 
and peroxisome proliferation study too. 





Phthalic Acid, Dicyclohexyl Ester 
L2 t-TDI: 0.1 mg/kg b.w. 
Available: Three 90-day oral rat studies, limited in vitro mutagenicity studies 
(RIVM, 1988). 
Needed: Tests for gene mutation and chromosome aberration in mammalian 
cells in vitro and reproduction and teratogenicity studies. 
Phthalic Acid, Diesters with Hexadecanol and/or Octadecanol 
L2 Group t-TDI 0.15 mg/kg b.w.(with 76120) 
Available: 3-month oral rat and teratogenicity studies, Ames test (RIVM doc. 
1990-09-11; CS/PM/529). 
Needed: Tests for gene mutation and chromosome aberration in mammalian 
cells in vitro, reproduction study and peroxisome proliferation study. 
Phthalic Acid, Diethyl Ester 
L2 t-TDI: 0.2 mg/kg b.w. 
Available: 3-month oral rat, mutagenicity, ip teratogenicity and peroxisome 
proliferation studies (Fd Cosmet Toxicol 1978, 16, 415-422; RIVM 
1986, June). 
Needed: Reproduction and teratogenicity studies. 
Phthalic Acid, n-Hexadecyl n-Octadecyl Ester 
L2 Group t-TDI 0.15 mg/kg b.w. (with 75040). 
6. The following substances are classified in list 7 with no restriction and require the data specified 
below: 
33040 Adipic Acid, Mono-n-Octadecyl Ester, Calcium Salt 
Needed: Hydrolysis studies. 
44320 Citric Acid, Monoisopropyl Ester 
Needed: Hydrolysis studies and reports from Duel et al, 1951. 
44400 Citric Acid, Mono-n-Octadecyl Ester 
Needed: Hydrolysis studies and reports from Duel et al, 1951. 
73360 Phosphoric Acid, Mono-n-Hexadecyl Ester 
Needed: Hydrolysis studies. 
[Waiting list as it is a new substance.] 
73440 Phosphoric Acid, Mono-n-Hexyl Ester 
Needed: Hydrolysis studies. 
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7. The following substances (which are not peroxisome proliferators) are classified in List 8 with no 







Azelaic Acid, Bis(2-Hydroxyethyl) Ester 
Azelaic Acid, Diphenyl Ester 
Phosphorous Acid, Triphenyl Ester 
Sebacic Acid, Diphenyl Ester 
Sulphosuccinic Acid, Dicyclohexyl Ester, Sodium Salt 
Sulphosuccinic Acid, ([2-[12-Hydroxy-l-Oxooleyl)-Amino]Ethyl] Ester, Disodium 
Salt 




2,2,4-Trimethyladipic Acid, Methyl Esters 



















Adipic Acid, Alkyl, Primary (C4-C13) Esters 
Adipic Acid, Esters with Diols from C2-C6 
Adipic Acid, Mixed Esters with 1,2-Propyleneglycol and Alcohols, Monoh., Sat., 
Linear (C8-C10) 
[Waiting list as it is a new substance] 
Azelaic Acid, Alkyl, Primary (C1-C12) Esters 
Citric Acid, Alkyl, Primary (C2-C12) Esters 
Phosphoric Acid, Ethanolamine Hexyl Branched and Linear Ester 
Phosphoric Acid, Mono- and Diesters with Alcohols, Aliph. (C9-C18), 
Diethanolamine Salt 
Phosphoric Acid, Mono- and Diesters with Alcohols, Aliph. (C9-C18), Salts 
Phosphoric Acid, Mono- and Diesters with Alcohols, Aliphatic, Monohydric, 
Saturated (C2-C4) 
Phosphoric Acid, Mono- and Diesters with Alcohols, Monohydric, Saturated, 
Primary, Linear (C12-C18), Diethanolamine Salt 
Phosphoric Acid, Mono- and Diesters with Alcohols, Monohydric, Saturated, 
Primary, Linear (C12-C18), Salts 
Phosphoric Acid, Nonyl Ester, Sodium Salt 
Phosphoric Acid, Octadecyl Esters 
[Waiting List as it is a new substance] 
Phosphoric Acid, Trialkyl(C4-C16) Ester 
Phosphoric Acid, Triethanol Ester 
Phosphoric Acid, Tris(ALkoxyalkyl C3-C8) Ester 
Phosphorous Acid, Trialkyl(C8-C12) Ester 
Reports of the Scientific Committee for Food (Thirty-sixth series)  79 2 JUNE 1995 CERTAIN ESTERS USED IN PLASTICS FOR FOOD CONTACT APPLICATIONS 
74600 Phthalic Acid, Bis(ALkoxyalkyl C3-C18) Ester 
74760 Phthalic Acid, Bis(Methylcyclohexyl) Ester 
75520 Phthalic Acid, Diisooctyl Ester 
76000 Phthalic Acid, Mixed Esters with Butyl Glycolate and Alcohols, Aliph., Monoh., 
(C1-C4) 
76080 Phthalic Acid, Mixed Esters with Ethyl Glycolate and Alcohols, Aliph., Monoh., 
(C1-C4) 
85040 Sebacic Acid, Alkyl(C6-C12) Esters 
91540 Sulphosuccinic Acid, Alkyl(C4-C20) Esters, Salts 
94680 Trimellitic Acid, Trialkyl(Cl-C8) Ester 
94720 Trimellitic Acid, Trialkyl(C7-C9) Ester 
94760 Trimellitic Acid, Triisooctyl Ester 
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Definition of the SCF lists 
Substances for which the committee was able to express an opinion 
List 0 
Substances, e.g. foods, which may be used in the production of plastic materials and articles, e.g. food 
ingredients and certain substances known from the intermediate metabolism in man and for which an 
ADI need not be established for this purpose. 
List 1 
Substances, e.g. food additives, for which an ADI, a temporary ADI (t-ADI), a MIDI, a PMTDI, a 
PTWI or the classification "acceptable" has been established by this Committee or by JECFA. 
Lisi 2 
Substances for which a TDI or a t-TDI has been established by this Committee. 
List 3 
Substances for which an ADI or a TDI could not be established, but where the present use could be 
accepted. 
Some of these substances are seLf-lirniting because of their organoleptic properties or are volatile and 
therefore unlikely to be present in the finished product. For other substances with very low migration, 
a TDI has not been set but the maximum level to be used in any packaging material or a specific limit 
of migration is stated. This is because the available toxicological data would give a TDI which 
allows that a specific limit of migration or a composition limit could be fixed at levels very much 
higher than the maximum likely intakes arising from present uses of the additive. 
List 4 
Substances for which an ADI or a TDI could not be established, but which could be used if the 
substance migrating into foods or in food simulants is not detectable by an agreed sensitive method. 
List 5 
Substances which should not be used. 
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Substances for which there were insufficient toxicological or technological data to enable 
the Committee to express an opinion 
List 6 
Substances for which there exist suspicions about their toxicity and for which data are lacking or are 
insufficient. 
The allocation of substances to this Hst is mainly based upon similarity of structure with that of 
chemical substances already evaluated or known to have functional groups that indicate carcinogenic 
or other severe toxic properties. 
Section 6A: Substances suspected to have carcinogenic properties. These substances should not be 
detectable in foods or in food simulants by an appropriate sensitive method for each 
substance. 
Section 6B: Substances suspected to have toxic properties (other than carcinogenic). Restrictions 
may be indicated. 
List 7 
Substances for which some toxicological data exist, but for which an ADI or a TDI could not be 
established. The required additional information should be furnished. 
List 8 
Substances for which no or only scanty and inadequate data were available. 
List 9 
Substances and groups of substances which could not be evaluated due to lack of specifications 
(substances) or to lack of adequate description (groups of substances ). 
Groups of substances should be replaced, where possible, by individual substances actually in use. 
Polymers for which the data on identity specified in "SCF Guidelines" are not available. 
Lisi W 
"Waiting list". Substances not yet included in the Community lists, as they should be considered 
"new" substances, i.e. substances never approved at national level. These substances are not susceptible 
to be included in the Community lists, lacking the data requested by the Committee. 
On the basis of the data lacking the waiting list is subdivided into: 
List W7 
Substances for which some toxicological data exist, but for which an ADI or a TDI could not be 
established. The required additional information should be furnished. 
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List W8 
Substances for which no or only scanty and inadequate data were available. 
List W9 
Substances and groups of substances which could not be evaluated due to lack of specifications 
(substances) or to lack of adequate description ( groups of substances ). 
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USED AS A MEAT TENDERISLNG AGENT 
EXPRESSED ON 2 JUNE 1995 
1. Terms of reference 
To advise on the safety of the use of papain as a meat tenderiser by injection into beef cattle after 
stunning and before bleeding. 
2. Background 
Papain was previously evaluated and found acceptable for chill-proofing of beer on the basis that it 
is a constituent of a part of a plant (papaya fruit) commonly consumed as a food source (80th meeting of 
the Scientific Committee for Food, October 1991). This was in accordance with the principles 
established by the Committee in its guidelines for the presentation of data on food enzymes (CEC, 
1992). 
The use of papain as a meat tenderiser by injection in solution into live animals before slaughtering 
has previously been practised in some Member States but has been discontinued on animal welfare 
grounds. The Committee has now been presented with a dossier describing an alternative method 
where the animals are stunned and pithed before they are injected with a sterile solution of papain in 
an oxidised, inactivated form and, shortly after, hoisted to the bleeding rail and then stuck. 
According to the dossier, this treatment would result in residue levels of papain of less than 1 mg/kg 
in muscle and up to 5 mg/kg in offal. 
3. Current review 
Papain has been in use for many years for medical purposes, in cosmetics and for various food purposes. 
Since it is an enzyme naturally present in food, papain has not been subject to the toxicity testing 
which is normally performed on food additives. With the exception of allergic reactions, cases of 
adverse effects reported in the literature (damage to the oesophagus following impaction of treated 
meat) have all been associated with high exposure from uses not comparable to the proposed one and 
it is unlikely that the small residues resulting from the proposed use would cause any such effects. 
The Committee is aware of reports in the literature indicating that papain has been associated with 
allergic reactions but the majority of cases were not relevant to oral exposure, mostly being associated 
with occupational exposure by the airborne route. Only a few cases of allergic responses to oral 
administration of papain have been reported (Mansfield and Bowers, 1983; Mansfield et al, 1985). 
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The Committee considered the evidence for the claim that the enzyme is not significantly activated 
until papain-treated meat is cooked. We were informed that: 
- Papain is injected into the stunned animal in a form inactivated by oxidation and will not be 
activated until the oxygen tension in the carcass is sufficiently low. 
This conversion to the activated form only occurs when the normal processes taking place in 
the carcass after death have also reduced the pH and rapid chilling has considerably 
reduced the temperature. Both these changes reduce the level of activity of activated 
papain. 
- Papain protease, unlike many other enzymes, has its optimum activity at 50-70°C, this 
optimum activity being considerably higher than that at ambient temperature. 
Traditional ageing of meat by storing over days/weeks involves the release of intrinsic 
proteases which, like papain, also degrade proteins. 
The Committee considered the question of whether meat treated with papain may be more susceptible 
to microbial deterioration. Enhanced protein degradation by papain increases soluble nitrogen content 
of meat which may stimulate microbial growth, mainly of those bacterial genera with high 
nutritional requirements. In one study, no significant differences were found between bacterial counts of 
surface samples of papain tenderised sirloin strip steaks and counts of control steaks. However, the 
internal meat tissue of papain tenderised beef cuts was frequently contaminated with bacteria 
whereas all samples of control beef cuts were free from bacteria (Anonymous, 1961). It has been shown 
experimentally that poor keeping quality of papain tenderised meat was associated with deep 
penetration of bacteria (Thomas, 1966). Spoilage problems with this type of meat were experienced 
after relatively short periods of storage (Hudson & Roberts, 1974). 
Formation of biogenic amines in fermented sausages is well documented (Eitenmiller et al. 1978; Eerola 
et al. 1993). Addition of an exogenous proteinase to the ingredients of dry fermented sausages 
enhanced the formation of free amino acids, and the higher amount of substrate in sausages with 
added proteinase available for the decarboxylase activity of the microbial flora resulted in an 
increase of up to nine-fold in tyramine content compared to that found in control sausage (Diaz et al. 
1993). If papain-tenderized meat is used for the preparation of fermented meat products, such as 
sausages, salami, etc., an increase in the amount of biogenic amines formed seems likely to occur. 
The Committee also considered whether meat treated with papain but otherwise unprocessed could 
give cause for health concern with respect to degradation of proteins. However, since papain degrades 
proteins to components which are also products of normal digestion, the Committee does not consider 
that the consumption of meat treated with papain would give any reasons for concern in this respect. 
4. Conclusion 
While the Committee recognises that considerations of animal welfare, organoleptic meat quality 
and appropriate consumer information are relevant factors to be considered, they do not fall within 
the remit of the SCF and should be considered by other relevant bodies. 
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The Committee noted that present rules would require that tenderised meat could not be marketed as 
fresh meat and that such meat should be properly labelled. If the use of injected papain as a meat 
tenderiser is authorised, then the Committee wishes to draw to the attention of the Commission the 
desirability of explicit labelling so that consumers who have acquired an allergy towards papain 
have an opportunity to avoid papain-treated meat. 
Given the general principle that enzymes derived from normal food sources may be considered as 
posing no health problems, and the lack of reports of adverse effects of the enzyme other than very 
occasional cases of allergic reactions, the Committee considers the use of papain as a meat tenderiser, 
administered to stunned and pithed animals before bleeding, is acceptable from the point of view of 
the safety of papain per se, provided the general provisions in the SCF guidelines on enzymes (CEC, 
1992) are followed. The bacteriological safety of the use of papain injection into beef as a meat 
tenderising procedure should be confirmed by pilot testing under different conditions, representative of 
actual hygienic conditions of slaughterhouses in the different member states of the EU. The safety of 
the use of papain-treated meat in the manufacture of fermented meat products with regard to the 
formation of biogenic amines should also be confirmed by comparison with the same products made 
from control untreated meat. 
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